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 Abstract 
 
An emerging anticancer strategy is to identify molecular targets that when inhibited 
pharmacologically, result in pleiotropic downstream effects on pathways relevant to the malignant 
phenotype, with particular reference to the development of resistance. 
In recent years, the molecular chaperone Hsp90 has emerged as leading example of such a target-
specific therapy. Heat-shock proteins are found at increased levels in many solid tumors and 
haematological malignancies. Their expression may account for the ability of malignant cells to 
maintain protein homeostasis even in the hostile hypoxic microenvironment of the tumor. Particularly, 
Hsp90 has emerged as a target for cancer therapy due to its critical roles in retaining the conformation 
and the function of its client proteins, many of which are associated with cancer pathology.  There are 
12 HSP90 inhibitors in clinical trials; all have potencies on the order of 7-35 nM in a cell-based assay 
and half-lives of 1-3 h in the plasma of rodents. These inhibitors may distribute preferentially to the 
tumors and may have longer half-lives in the tumors than in the plasma, as in the case of 17-AAG and 
its active metabolite. However, side effects and poor formulability of 17-AAG restricted its potential 
of clinical application and motivated many groups to synthesize new compounds. The aim of this 
project is to identify new Hsp90 inhibitors which could overcome the limitations of available 
inhibitors and exhibit therapeutic advantages in terms of specificity, therapeutic index and antitumor 
efficacy. Several compounds have been tested during these years, especially a series of mold 
metabolites of Ascomycetes, structurally belonging to the class of azaphilones, were found to inhibit 
the heat shock protein Hsp90. In particular, bulgarialactone B was tested for its binding to Hsp90 
using surface plasmon resonance and limited proteolysis assays and for its effects on Hsp90 client 
proteins expression in a series of human tumor cell lines. This compound showed high affinity for 
Hsp90, interacting with the 90–280 region of the N-terminal domain and down-regulated the Hsp90 
clientproteins Raf-1, survivin, Cdk4, Akt, and EGFR. Bulgarialactone B and other natural azaphilones 
showed antiproliferative activity in a panel of human tumor cell lines; their conversion into 
semisyntheticderivatives by reaction with primary amines increased the antiproliferative activity. 
Preliminary results indicated in vivo activity of bulgarialactone B against an ascitic ovarian carcinoma 
xenograft, thus supporting the therapeutic potential of this novel series of Hsp90 inhibitors.  
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Moreover, to identify favourable interactions between Hsp90 inhibitors and target-specific agents, 
combinations between curcumin and two well-known HDAC inhibitors (vorinostat and 
panobinostat), have been tested. Curcumin, a natural polyphenol, has been described to exhibit 
effects on signaling pathways, leading to induction of apoptosis. In this study, we observed that 
curcumin inhibited Hsp90 activity causing depletion of client proteins implicated in survival 
pathways. Based on this observation, the study was designed to investigate the cellular effects of 
curcumin combination with the pan- HDAC inhibitors, vorinostat and panobinostat, which induce 
hyperacetylation of Hsp90, resulting in inhibition of its chaperone function. The results showed that, 
at subtoxic concentrations, curcumin markedly sensitized tumor cells to vorinostat- and panobinostat-
induced growth inhibition and apoptosis. The sensitization was associated with persistent depletion of 
Hsp90 client proteins (EGFR, Raf-1, Akt, and survivin). In conclusion, our findings document a novel 
mechanism of action of curcumin and support the therapeutic potential of curcumin/HDAC inhibitors 
combination, because the synergistic interaction was observed at pharmacologically achievable 
concentrations, which were ineffective when each drug was used alone. 
       Another new therapeutic target is GGT (gamma-glutamyl transferase), the interest in this enzyme 
is related to recent evidence supporting that it is implicated in tumor progression and in drug 
resistance to stress-inducing agents (i.e. platinum compounds). The extracellular γ-
glutamyltransferase-mediated metabolism of glutathione has been implicated in prooxidant events 
which may have impact on cellular functions including drug resistance. Therefore the objective of this 
approach was to investigate the role of GGT in response to various stress-inducing agents. The study 
was performed in two GGT-transfected melanoma clones to explore the hypothesis that GGT 
expression in tumour cells is implicated in modulation of cell behaviour under stress conditions. Our 
results show that GGT-overexpression in melanoma cells was associated with resistance to oxidative 
stress produced by prooxidant agents such as hydrogen peroxide and ascorbic acid. In GGT-
overexpressing cells, ability to tolerate oxidative stress was evidenced by the presence of a moderate 
level of ROS and lack of DNA damage response following treatment with H2O2. Cellular response to 
oxidative stress induced by ascorbic acid was detectable only in the clone with low GGT activity 
which also exhibited an increased susceptibility to apoptosis. The increased resistance of the GGT-
overexpressing clone was not related to intracellular GSH content but rather to the increased 
 expression of catalase and to a reduced efficiency of iron-mediated formation of toxic free radicals. 
Taken together, these findings are consistent with a contribution of GGT in the mechanisms of drug 
resistance, because induction of oxidative stress is a relevant event in the apoptotic response to 
cytotoxic agents. 
Again, in an attempt to develop novel strategies for overcoming the mechanisms of cellular protection 
against oxidative stress, we have explored the efficacy of the combination of two prooxidant agents in 
the two human melanoma cell clones differently expressing GGT. The γ-glutamyltransferase-
overexpressing clone exhibited a low susceptibility to arsenic trioxide-induced apoptosis, associated 
with low reactive oxygen species induction and increased catalase activity. The combination of 
arsenic trioxide with subtoxic concentrations of ascorbic acid resulted in a sensitization to apoptotic 
cell death. The expression of protective mechanisms, in particular catalase activity, accounted for the 
behavior of the resistant clone. The sensitization achieved by the combination was associated with a 
cellular response involving the ASK1/p38 axis, which is implicated in the regulation of catalase 
expression and the activation of apoptotic signals. In conclusion, the results of our study provide 
evidence that a rational combination of prooxidant agents may be effective in overcoming cellular 
tolerance to oxidative stress. 
Moreover, as a number of recent observations have suggested a potential role for membrane-bound 
gammaglutamyltransferase (GGT) in tumor progression through redox interactions leading to 
production of reactive oxygen species, we performed a study to evaluate whether such pro-oxidant 
activity of GGT can promote oxidative DNA damage, thus contributing to cancer genomic instability. 
Human GGT-transfected melanoma cells were studied, and DNA damage was measured by using the 
alkaline comet assay. Our results indicate that higher levels of GGT activity are associated with 
higher levels of background DNA damage and oxidized bases. This association cannot be explained 
by differences in cell cycle distribution or apoptotic rates. GGT-over-expressing cells also presented 
with a markedly higher glucose uptake, a phenomenon potentially leading to higher metabolic rate 
and oxidative DNA damage. Anyway, when GGT-over-expressing cells were incubated in the 
presence of GGT substrates and a source of catalytic iron, increased levels of DNA damage and 
oxidized bases were observed, an effect completely prevented in the presence of GGT inhibitors or 
various antioxidants. The findings reported indicate that GGT activity is able to promote iron-
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dependent DNA oxidative damage, thus potentially representing an important mechanism in 
initiation/progression of neoplastic transformation.
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 Introduction 
 
The resistance of many types of cancer to chemotherapies represents the major hurdle in 
successful cancer treatment. Cancer cells can escape the toxic effect of most commonly used 
drugs despite their different chemical structure and intracellular targets. The mechanisms 
underlying the failure of chemotherapeutic drugs have been well studied. Activation of 
survival/antiapoptotic pathways is a common feature of cancer cells that converge in the 
development of cellular resistance to cytotoxic agents. The advent of drugs targeting tumor-
associated prosurvival alterations of cancer cells has changed the interest of antitumor drug 
development from cytotoxic drugs to target-specific agents. Although single-agent therapy 
with molecularly targeted agents has shown limited success in tumor growth control, a 
promising strategy is represented by the development of rational combinations of target-
specific agents and conventional antitumor drugs. The available evidence supports the 
interest of rationally designed approaches to enhance the efficacy of conventional antitumor 
treatments through the inhibition of survival pathways and the notion that the concomitant 
targeting of multiple pathways may be a successful strategy to deal with tumor heterogeneity 
and to overcome drug resistance of tumor cells [1]. 
The survival pathways implicated in cellular response to drug treatment are primarily 
PI3K/Akt and Ras/MAPK, which also mediate the signalling activated by growth factors and 
play a role in the regulation of critical processes including cell proliferation, metabolism, 
apoptosis and angiogenesis.  
Targeting Hsp90, which acts as a molecular chaperone for survival factors including Akt, 
may have the potential advantage to simultaneously block multiple oncogenic pathways.  
Cancer cells use the HSP90 chaperone machinery to protect an array of mutated and over 
expressed oncoproteins from misfolding and degradation. Therefore, HSP90 is recognized as 
a crucial facilitator of oncogene addiction and cancer cell survival. In the past 5 years, the 
complex nature of HSP90 regulation and the many ways in which it participates in cell 
physiology have been clarified. Considerable progress has been made in understanding the 
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dynamic conformational flexibility of HSP90 and in recognizing the contribution made by 
post-translational modifications to the regulation of the HSP90 chaperone machine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Current models propose that ATP binding and hydrolysis, as well as a precisely sequenced 
interaction with an array of co-chaperones, subtly shift the conformational equilibrium of 
Hsp90, presumably by lowering the energy barrier between certain conformations, thus 
providing directionality to the HSP90 cycle. ATP binding to the undimerized (open) amino 
terminal (N) domain of HSP90 promotes repositioning of a ‘lid’ segment (red) that leads to 
transient dimerization of the N domains. Subsequent structural rearrangements result in the 
‘closed and twisted’ conformation of HSP90 that is committed to ATP hydrolysis. Binding of 
the co-chaperone activator of HSP90 ATPase 1 (AHA1) enhances the rate of ATP 
hydrolysis-dependent HSP90 cycling by increasing the rate of the conformational alterations 
that result in the acquisition of ATPase competence. The dashed arrow reflects the difficulty 
of HSP90 in achieving the ATPase-competent conformation in the absence of AHA1. The co-
chaperones STIP1 (also known as p60HOP) and cell division cycle 37 homologue (CDC37), 
and N domain-binding HSP90 inhibitors, exert an opposite effect to that of AHA1 by 
preventing the initial structural changes necessary for N domain dimerization. Prostaglandin 
E synthase 3 (PTGES3; also known as p23) slows the ATPase cycle by stabilizing the closed 
conformation that is committed to ATP hydrolysis [2]. 
C, carboxy-terminal domain;  
M, middle domain;  
Pi, inorganic phosphate 
 HSP90 inhibitors currently under clinical evaluation interact with the N domain ATP-binding 
pocket, prevent ATP binding and stop the chaperone cycle, leading to client protein 
degradation. There are now 13 HSP90 inhibitors undergoing clinical evaluation, and 23 
active HSP90 inhibitor oncology trials. Although there are currently no approved HSP90-
targeted drugs, there has been considerable progress on several fronts, and potential routes to 
approval are becoming apparent. One important advance has been in the drugs themselves. 
17-AAG is undergoing Phase III evaluation with an improved formulation that overcomes 
several toxicities that were common to earlier trials. At the same time, several chemically 
distinct HSP90 inhibitors with improved properties, including oral biological availability, 
have recently entered the clinic or will soon undergo clinical evaluation. A second area of 
advance is in choosing the appropriate indication. Recent preclinical and disease-specific 
clinical studies have illuminated some key points to consider in the further development of 
HSP90 inhibitors. Optimal development of HSP90-directed therapeutics will depend also on 
synthesizing information gained from careful genetic analysis of primary and metastatic 
tumours with an understanding of the unique environmental context in which the tumour is 
thriving at the expense of the host. 
Pathways involved in ROS-adaptive response may also play a critical role in protecting cells 
against cytotoxic effects of anticancer agents, thus supporting the hypothesis of a correlation 
between adaptation/resistance to oxidative stress and resistance to anticancer drugs. One of 
the major aims is thus to highlight the adaptive mechanisms and their interplay in the intricate 
connection between oncogenic signaling, oxidative stress, and chemoresistance. Clarification 
of these mechanisms has tremendous application potential, in terms of developing novel 
molecular-targeted anticancer therapies and innovative strategies for rational combination of 
these agents with chemotherapeutic or tumor-specific biologic drugs [3]. 
A number of recent observations have suggested a potential role for membrane-bound 
gamma-glutamyltransferase (GGT) in tumor progression and appearance of more aggressive 
and resistant phenotypes, through redox interactions leading to production of reactive oxygen 
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species. γ-Glutamyltransferase (GGT) shows a dysregulated expression in several tumour 
types, but its role in malignant behaviour and tumour progression is still a matter of 
investigation.  
 
The increased cell resistance against pro-oxidant drugs and other potentially lethal oxidant 
challenges was generally interpreted as a result of GGT-dependent facilitation of cysteine 
uptake, a factor favouring the increase of intracellular antioxidant GSH. However, recent 
studies have documented that GGT-mediated metabolism of extracellular GSH in the 
presence of extracellular transition metal ions can also exert pro-oxidant effects at the 
membrane surface level, with generation of reactive oxygen species (ROS). This 
phenomenon is explained with the high reactivity of GGT-product cysteinyl-glycine, which is 
in fact able to reduce extracellular transition metal cations (Fe3+ and others) more efficiently 
than does GSH itself. Such metal ion ‘redox cycles’ was shown to produce ROS and other 
 free radicals, i.e. reactive species capable of promoting several intra- and extra-cellular 
biomolecular effects. On this basis, GGT was suggested to be an additional source of (low 
levels of) endogenous ROS that could contribute to the “persistent oxidative stress” 
repeatedly described in genomic instability, carcinogenesis and induction of protective 
systems involved in detoxification and/or resistance to cytotoxic agents [4]. 
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Aims 
 
Since drug resistance is becoming one of the major causes of anti-cancer therapy failure, new 
pharmacological approaches are welcoming in order to increase the success in the therapy 
outcome. Inhibition of HSP90 can lead to the simultaneous degradation of a large number of 
oncogenic proteins thus this protein has become a target of interest for oncology. A major 
advantage of HSP90 inhibitors is that attacking several pathways necessary for cancer 
development, they reduce the ability of the tumor to acquire resistance to any single 
therapeutic pathway. It has also been proposed that HSP90 occurs in an activated form in 
cancer cells, whereas in normal somatic cells only the latent form is found. This has given 
rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the 
activated form and thus more specifically target cancer cells. 
However, side effects and poor formulability of currently available Hsp90 inhibitors 
restricted their potential of clinical application and motivated many groups to synthesize new 
compounds. Given such a background our aim was to: 
1. identify new Hsp90 inhibitors which could overcome the limitations of available 
inhibitors and exhibit therapeutic advantages in terms of specificity, therapeutic index and 
antitumor efficacy, 
2. identify new drug combinations between Hsp90 inhibitor and conventional therapy to 
overcome the limitations of drug resistance 
Another critical feature of the molecular mechanisms implicated in the drug resistance 
phenomenon is the oxidative stress balance. A complex intracellular redox buffering network 
is used by cells to adapt and protect against the dangerous effects of oxidative stress. 
However, pathways involved in ROS-adaptive response may also play a critical role in 
protecting cells against cytotoxic effects of anticancer agents, thus supporting the hypothesis 
of a correlation between adaptation/resistance to oxidative stress and resistance to anticancer 
drugs. Gamma-glutamyltransferase (GGT) is a key enzyme involved in glutathione 
metabolism and whose expression is often significantly increased in human malignancies. In 
 the past years, several studies focused on the possible role of GGT in tumor progression, 
invasion and drug resistance. The involvement of a pro-oxidant activity of GGT, besides its 
early recognized contributions to cellular antioxidant defenses, has been repeatedly 
documented. 
GGT-derived pro-oxidants can modulate important redox-sensitive processes and functions 
of the cell, with particular reference to its proliferative/apoptotic balance, which has obvious 
and important implications in tumor progression and drug resistance. Given these findings it 
could be of interest to focus:  
1. the role of GGT-mediated oxidative stress in cancer progression and drug resistance, 
and possibly identify therapeutic stategies to overcome it, 
2. whether the pro-oxidant activity of GGT can promote oxidative DNA damage, thus 
contributing to cancer genomic instability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14
Material and Methods 
 
1. Cell lines and culture conditions 
 
The human ovarian carcinoma cell line IGROV-1, the human melanoma cell line JR8, and the human 
epithelial carcinoma cell line A431 were routinely grown in RPMI 1640 (Lonza, Vierviers, Belgium), 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (GIBCO, Invitrogen, Paisley, UK). 
The human peritoneal mesothelioma cell line STO was kindly provided by Dr. N. Zaffaroni (IRCCS 
Istituto Nazionale Tumori, Milan) and grown in 50/50 DMEM-Ham’s F12 medium (Lonza, Vierviers, 
Belgium), supplemented with 10% (v/v) heat-inactivated fetal bovine serum and 2mM L-glutamine 
(L-Gln). All these cell lines were maintained at 37° C in a 5%/95% CO2/air atmosphere. 
Two human melanoma cell clones expressing different GGT activity and obtained as previously 
described [5] were used. Briefly, the c21/GGT clone and the c21/basal clone expressing high (90.78 ± 
3.40 mU/mg of cellular protein) and low (0.34 ± 0.13 mU/mg of cellular protein) GGT activity 
respectively, were obtained by stable transfection of low-expressing GGT activity Me665/2/21 clone 
(c21) with the full-length cDNA of human GGT. Cells were routinely grown in RPMI 1640 medium, 
supplemented with 10% (v/v) heat-inactivated foetal bovine serum, 2 mM L-glutamine (L-Gln) and 
0.5 mg/ml G418 (Gibco), at 37 °C in a 5%/95% CO2/air atmosphere. 
2. Drugs and treatment conditions 
 
All the compounds tested (the series of mold metabolites of Ascomycetes and their semisyntetic 
derivatives) were obtained as powders from the laboratory of Prof. Merlini (University of Milan) and 
freshly prepared dissolving powder in dimethylsulfoxide (DMSO) (BDH Prolabo, Milan, Italy) with 
following dilution in culture medium. Cells were incubated with these drugs for 6, 24 or 72 h 
(depending on the assay), at 37° C in culture medium supplemented with 10%(v/v) heat-inactivated 
fetal bovine serum; drug concentrations used for each assay are reported in the Results section. 
Panobinostat was synthesized as described in the recent US patent application (6,552,065). Vorinostat 
was provided by BIOMOL International LP (Plymouth Meeting, PA, USA). Curcumin was provided 
by Sigma Chemical (St. Louis, MO, USA). Stock solutions of all these drugs (10 mg/ml) were 
prepared in dimethyl sulfoxide (DMSO) (BDH Prolabo, Milan, Italy) and maintained at -20° C. 
Before each experiment, drugs were diluted in DMSO and used at the concentrations reported in the 
Results section. 17-AAG was obtained from InvivoGen (San Diego, USA) and it was provided as a 
 stock solution (5 mM) that we freshly diluted in culture medium before each experiment. Bortezomib 
was also stocked in 10 mg/ml DMSO solutions, but dilutions were freshly prepared in sterile water. 
Experiments were performed by incubating cells with drugs for 4, 24, or 72 h at 37° C in culture 
medium supplemented with 10% (v/v) heat inactivated foetal bovine serum. 
Experiments with hydrogen peroxide (H2O2, 3% solution in water; OLCELLI Farmaceutici, Italy), 
ascorbic acid (AA,1000 mg/5 ml; S.A.L.F., Italy) and arsenic trioxide (As2O3, solutions used for each 
experiment were freshly prepared following dilution in sterile/distilled water, using a DMSO stock 
solution of 1 mg/ml (5.05 mM) stored at -20°C) were performed by incubating cells for 2 h at 37° C 
in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated foetal calf serum. Cells were 
then washed and maintained in culture medium for 24 or 72 hours depending on the assay. The 
exposure time (2 h) was chosen to avoid a marked cytotoxicity of arsenic trioxide and to allow the 
investigation of drug interaction. In a separate set of experiments, incubations with AA were 
performed in the presence of glutathione (GSH, 0.5 mmol/L) and glycyl-glycine (glygly, 20 mmol/L), 
in order to achieve full activation of GGT. Some experiments were performed in the presence of the 
iron chelators deferoxamine mesylate (DFO; 500 µM) and 2, 2’-bipyridyl (BIP; 500 µM) and the 
antioxidant catalase (200 U/ml). 
For basal levels of DNA damage, cells were harvested 24 h after seeding. Where indicated, the GGT 
competitive inhibitor l-2-amino-4-boronobutanoic acid (20 µM; ABBA) was sterile filtered and added 
to incubation media. ABBA was kindly provided by Dr. R.E. London (Natl. Inst. Environ. Health 
Sci., NC, USA); in preliminary experiments a 20 µM concentration of ABBA caused a strong 
inhibition of GGT activity but no significant effects on cell proliferation (data not shown). For 
stimulation of GGT activity, complete culture medium was replaced with RPMI medium containing 
GSH (2 mmol/L), ADP-chelated FeCl3 (2–0.2 mmol/L) and glycyl-glycine (20 mmol/L). Incubations 
were started by adding ADP-Fe3+ to incubation mixtures, in the presence or absence of glycyl-
glycine. The latter served as acceptor for transpeptidation and was added to stimulate GGT activity. 
Incubations were performed for 60 min at 37 ◦C in a 5%/95% CO2/air atmosphere. At the end of this 
time, cells were washed two times and harvested for comet assay. In separate sets of experiments, 
inhibition of GGT activity was obtained by adding to incubation mixtures GGT competitive inhibitors 
serine/boric acid (20/20mM) complex (SBC) or ABBA (20 µM). Where indicated, soluble GGT 
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(100mU/mL), deferoxamine mesylate (DFO; 3 mM), erythrocyte CuZn/SOD (500 U/mL), thymolfree 
liver catalase (400 U/mL), α-tocopherol (200 µmol/L), butylated hydroxytoluene (BHT; 200 µmol/L) 
or Trolox C (1 mmol/L) were added to incubation mixtures.  
3. Anti-proliferative assay 
 
Cell sensitivity to all the tested compounds was determined by a growth inhibition assay. Briefly, cells 
were seeded in 12-well plates (50,000 or 40,000 cells/well, depending on the cell line), 24 h before 
experiments. Cells were exposed to the drugs for 72 h to allow approximately three replications in the 
control cells. In a separate set of experiments, after 24 h of treatment, cells were incubated in drug-
free medium for 72 h. Cell sensitivity to hydrogen peroxide, ascorbic acid and arsenic trioxide was 
determined after 2 h of exposition to the drugs. Then cells were washed, medium was changed, and 
cultures were grown up to 72 h. 
Adherent cells were then trypsinized and counted with a cell counter (Beckam Coulter, Fullerton, CA, 
USA). IC50 values, derived from dose–response curves, were defined as drug concentrations required 
for 50% inhibition of cell growth. 
4. Protein expression analysis 
 
Total cell lysates were prepared rinsing cells twice with ice-cold PBS supplemented with 0.1 mM 
sodium orthovanadate, then lysing them in hot sample buffer as previously described [23]. After 
determination of protein concentration (BCA Protein Assay Reagent, Pierce, Thermo Fisher 
Scientific, Rockford, IL, USA), whole-cell extracts were separated by SDS polyacrylamide gel 
electrophoresis (PAGE) and transferred onto nitrocellulose membranes. Detection of proteins was 
accomplished using horseradish peroxidase-conjugated secondary antibodies and a 
chemiluminescence reagent purchased through Amersham Biosciences (Rockford, IL). Primary 
antibodies used in this study are: anti-Raf-1 (sc-133) and anti-Cdk4 (sc-601) (Santa Cruz 
Biotechnology, CA, USA), anti-EGFR (Upstate Biotechnology, Millipore, Billerica, MA,USA), anti-
Survivin and anti-p23 and anti-Hsc70 (Abcam,Cambridge, UK), anti-Akt (Transduction 
Laboratories,Lexington, USA), anti-PARP-1 (Calbiochem, MerckChemicals, Nottingham, UK), anti-
Cleaved Caspase-3 (Asp175) (Cell Signaling Technology, Inc., MA, USA), anti-p53 (Dako, Glostrup, 
Denmark), anti-Bcl-2 (Dako, Denmark), anti-Bax (BD Pharmingen, USA), anti-γ-H2AX (Upstate 
Biotechnology, USA), anti-RPA-2 (NeoMarker, USA), anti-cytochrome C (BD Pharmingen), anti-
 phospho-p53(Ser15) (Cell Signaling Technology, USA) anti-RPA-2 (NeoMarker, Thermo Fisher 
Scientific, Fremont, CA, USA), anti-cytochrome C (BD Pharmingen), anti-phospho-p53(Ser15), anti-
phospho-p38 (Thr180/Tyr182) and anti-phospho-ASK1 (Thr845) (Cell Signaling Technology, 
Danvers, MA, USA), anti-LC3 B I/II (Abcam, Cambridge, UK) anti-Actin and anti-Tubulin (Sigma 
Chemical Co., St. Louis, MO, USA). Quantification of western blot analyses was obtained by Image 
Quant 5.2 program. 
For determination of cytochrome C release from mitochondria, melanoma cells were exposed to 
equitoxic concentrations of arsenic trioxide (1 µM and 5 µM for c21/basal and c21/GGT, respectively) 
and ascorbic acid (0.03 mM and 0.06 mM, respectively), alone or in combination, for 2 h. Floating 
and adherent cells were harvested and cytosolic extracts were prepared as described previously. 
Briefly, to maintain the integrity of mitochondria, cells were disrupted by a Dounce homogenizer (30 
strokes) in ice-cold lysis buffer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM 
EDTA, 1 mM EGTA, 250 mM sucrose, 0.5 mM phenyl-methyl-sulfonyl fluoride, 10 µg/ml leupeptin, 
10 µg/ml aprotinin and 10 µg/ml trypsin inhibitor), then samples were centrifuged at 20,000 g for 20 
min. Supernatants were stored at –70°C until gel electrophoresis. Cytosolic protein extracts (80 µg) 
were separated on a 15% SDS-PAGE gel and processed for Western blot analysis. 
5. Co-immunoprecipitation and immunoblot analysis 
 
Following the designated treatments, cells were lysed in NET buffer [50 mmol/L Tris (pH 7.4), 150 
mmol/L sodium chloride, 0.1% NP40, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L EDTA, 
2.5 lg/mL leupeptin, 5 lg/mL aprotinin] first for 30 min on ice and then for 30 min at 4 °C in rotation 
on a wheel. Nuclear and cellular debris were cleared by centrifugation (10,000g, 10 min, and 4 °C). 
Total cellular proteins were then quantified using the BCA protein assay. Cell lysates (500 µg) were 
incubated with the Raf-1 or Hsp90 polyclonal-specific monoclonal antibodies (Santa Cruz 
Biotechnology Inc., CA, USA) for 2 h at 4 °C. Protein A-sepharose (Sigma–Aldrich, Germany) (90 
µL), previously prepared in TNT solution (20 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% Triton X-
100) was added to the lysates and incubated overnight at 4 °C. The immunoprecipitates (separated by 
centrifugation 15,000g, 2 min, 4 °C) were washed twice in NET buffer and twice in PBS with 1% 
aprotinin and 1 mmol/L PMSF. Proteins were eluted with the SDS sample loading buffer before the 
immunoblot analyses with specific antibodies against Raf-1, Hsp90 or Hsp70 (Santa Cruz 
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Biotechnology Inc., CA, USA), p23 or Hsc70 (Abcam). Quantification of western blot analyses was 
obtained by Image Quant 5.2 program. 
6. Determination of apoptosis 
 
Apoptosis was determined by TUNEL assay (Roche) 72 h after the start of the treatment. The time of 
exposure to drugs depend on the assay and is indicated in the Results section. Treated cells were fixed 
in 4% paraformaldehyde (RT, 45 min), washed and resuspended in ice-cold PBS. The in situ cell 
death detection kit (Roche, Germany) was used according to the manufacturer’s instructions, and 
samples were analyzed by flow cytometry (FACScan; Becton-Dickinson, Franklin Lakes, NJ, USA). 
7. Fluorescence polarization assay 
 
GM-FITC, supplied by Invivogen (06C23-MT, California 92192, USA), was previously dissolved in 
DMSO to obtain 10 mM stock solutions and kept at -20 °C until use. HSP90, purchased from 
Stressgen (cat. No. SPP-776, Victoria BC, Canada), was previously dissolved in assay buffer (HFB) 
to form 2.2 µM stock solutions and kept at -80 °C until use. The compounds were previously 
dissolved in DMSO to obtain stock solutions and kept at -20 °C. The day of experiment, the 
compounds were prepared by serial dilutions in assay buffer (HFB) containing 20 mM HEPES (K) pH 
7.3, 50 mM KCl, 5 mM MgCl2, 20mMNa2MoO4, and 0.01% NP40. Before each use, 0.1 mg/mL 
bovine gamma globulin and 2 mM DTT were freshly added. Fluorescence polarization (FP) was 
performed in Opti-Plate™-96F well plates (Perkin Elmer, Zaventem, Belgium) using a plate reader 
(Wallac Envision 2101 multilabel reader, Perkin Elmer, Zaventem, Belgium) To evaluate the binding 
affinity of the molecules, 50 µL of the GM-FTC solution (5 nM) were added to 30 nM of HSP90 in 
the presence of 5 µL of the test compounds at increasing concentrations. The plate was mixed on a 
shaker at 4 °C for 4 h, and the FP values in mP (millipolarization units) were recorded. 
The IC50 values were calculated as the inhibitor concentration where 50% of the tracer is displaced; 
each data point is the result of the average of triplicate wells, and was determined from a plot using 
nonlinear least-squares analysis. Curve fitting was performed using Prism GraphPad software 
program (GraphPad software Inc., San Diego, CA). 
 
 
 
 8. Surface plasmon resonance analyses 
 
SPR analyses were performed using a Biacore 3000 optical biosensor equipped with research-grade 
CM5 sensor chips (Biacore AB). Using this platform, two separate recombinant Hsp90 surfaces, a 
BSA surface and an unmodified reference surface, were prepared for simultaneous analyses. Proteins 
(100 lg/ml in 10 mM sodium acetate, pH 5.0) were immobilized on individual sensor chip surfaces at 
a flow rate of 5 µl/min using standard amine-coupling protocols [7] to obtain densities of 8–12 kRU. 
Compound 2 and radicicol were dissolved in 100% DMSO to obtain 4 mM solutions, and diluted 
1:200 (v/v) in PBS (10 mM NaH2PO4, 150 mM NaCl, pH 7.4) to a final DMSO concentration of 
0.5%. Compounds concentration series were prepared as twofold dilutions into running buffer: for 
each sample, the complete binding study was performed using a six-point concentration series, 
typically spanning 0.05–10 µM, and triplicate aliquots of each compound concentration were 
dispensed into single-use vials. Included in each analysis were multiple blank samples of running 
buffer alone [8]. Binding experiments were performed at 25°C, using a flow rate of 50 µL/min, with 
60 s monitoring of association and 200 s monitoring of dissociation. Simple interactions were 
adequately fit to a single-site bimolecular interaction model (A+B =AB), yielding a single KD. 
Sensorgram elaborations were performed using the Biaevaluation software provided by Biacore AB 
[9]. 
9. Limited proteolysis  
 
Limited proteolysis experiments were performed at 37 °C, PBS 0.1% DMSO, at a 3 µM recombinant 
human Hsp90α concentration using trypsin, chymotrypsin and endoprotease V8 as proteolytic agents; 
30 µL of solution were used for each experiment. Binary complexes Hsp90/inhibitor were formed by 
incubating the protein with a 10:1 M excess of the individual inhibitor at 37°C for 15 min prior to 
proteolytic enzyme addition. Each complex was digested using a 1:100 (w/w) enzyme to substrate 
ratio. The extent of the reactions was monitored on a time-course basis by sampling the incubation 
mixture after 5, 15, and 30 min of digestion. Samples were desalted by ziptip C4 (Millipore) and the 
proteolytic fragments were analyzed by MALDITOF/MS using a MALDI-MX micro (Waters). In 
order to optimize sensitivity and accuracy of the mass measurements, three different m/z ranges were 
explored for each sample: a first range, from m/z 500 to 3,500 was analyzed in reflector mode; the 
other two ranges, from m/z 3,500 to 20,000 and from m/z 20,000 to 95,000, were analyzed in linear 
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mode. Each m/z range was calibrated using a suitable peptide or protein mixture. Mass data were 
elaborated using the Masslynx software (Waters). Preferential hydrolysis sites on Hsp90 under 
different conditions were identified on the basis of the fragments released during the enzymatic 
digestions. When comparative experiments were carried out on Hsp90 in the presence or in the 
absence of inhibitors, differences in the susceptibility of specific cleavage sites were detected, from 
which protein regions involved in the conformational changes could be inferred [10]. 
10. Yeast Hsp82 protein expression and purification 
 
Escherichia coli strain BL21-CodonPlus (DE3)-RIL (Stratagene; La Jolla, CA) was transformed with 
the plasmid pET28-Hsp82/NdeI containing the full-length Hsp82 gene of Saccharomyces cerevisiae, 
with an N-terminal His6 tag for purification. Transformed cells were selected on LB agar, containing 
50 µg/mL kanamycin and 40 µg/mL chloramphenicol, and a preliminary analysis on individual 
colonies was performed to evaluate their overexpressing ability. A 4 L culture of the clone with the 
highest Hsp82 expression was grown in the presence of kanamycin until A600 reached 1.2, and then 
expression of His-tagged Hsp82 was induced by the addition of 1 mM isopropyl-1-thio-b-D-
galactopyranoside. Cells were then grown for 3 h and harvested by centrifugation at 7000 rpm for 30 
min, at +4 °C. Harvested cells were washed in ice-cold 1X PBS, weighed and then stored at -70 °C. 
Frozen cells were thawed and then re-suspended and lysed in B-PER_ Bacterial Protein Extraction 
Reagent (Pierce; Rockford, IL), containing phenylmethylsulfonyl fluoride (PMSF). The lysate was 
centrifuged at 27,000g for 15 min at +4 °C and supernatant was ultra-centrifuged at 100,000g for 45 
min at +4 °C. Supernatant was then loaded, at a flow rate of 1 mL/min, onto a Ni–NTA column 
(HisTrap™ HP Columns, GE Healthcare) prepacked with NiSepharose and activated according to 
manufacturer’s instructions. The column was washed with potassium phosphate buffer (pH 7.4) 
containing 30 mM imidazole. A linear gradient of imidazole in potassium phosphate buffer was 
finally applied to the column for Hsp82 elution. The collected fractions were pooled, then subjected to 
gel filtration on Superdex 200 resin (GE Healthcare) in 20 mM Tris–HCl, pH 7.5, containing 300 mM 
KCl and 1 mM EDTA, and finally stored at -80 °C in the presence of glycerol (10% final 
concentration). 
 
 
 
 11. Determination of yeast Hsp90 ATPase activity  
 
Inhibition of the intrinsic ATPase activity of full-length recombinant yeast Hsp82 was measured by a 
modified enzymatically coupled ATPase assay, in which the amount of inorganic phosphate released 
by HSP90-dependent ATP hydrolysis is utilized by maltose phosphorylase, which phosphorylates 
maltose and then cleaves the disaccharide to produce glucose and glucose-1-phosphate. Glucose is a 
substrate for glucose oxidase, which uses atmospheric oxygen to produce gluconolactone and 
hydrogen peroxide. Finally, horseradish peroxidase consumes hydrogen peroxide by the oxidation of 
the colorless N-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red) to provide the Resorufin product, 
which has unique absorption spectra at 563 nm. For every molecule of ATP, that is, hydrolyzed by 
yeast Hsp90, one molecule of Amplex Red is ultimately oxidized to Resorufin. Inhibition of yeast 
Hsp82 ATPase activity by test compounds  was tested, following 3 h incubation in the presence of 
500 Lm ATP, in 96-well cell culture cluster clear plates by using a commercially available kit 
(PiPer™ Phosphate Assay kit; Molecular Probes, Eugene, OR), according to manufacturer’s 
instructions. To determine IC50 values, several appropriate concentrations of test compounds were 
evaluated depending on their relative potency. Each assay plate was run with a positive control which 
consisted of three wells containing the well-known Hsp90 inhibitor 17-DMAG, at a final 
concentration of 20 µM. 
12. Animals 
 
Experiments were carried out using female athymic Swiss nude mice, 8–10 weeks old (Charles River, 
Calco, Italy). Mice were main- tained in laminar flow rooms keeping temperature and humidity 
constant. Mice had free access to food and water. Experiments were approved by the Ethics 
Committee for Animal Experimentation of the Istituto Nazionale Tumori of Milan according to 
institutional guidelines. 
13. Intraperitoneally growing tumor 
 
The human IGROV-1 ovarian carcinoma was adapted to grow ip and maintained by serial ip passages 
of ascitic cells into healthy mice. Ascitic tumor cells 2.5 x 106 in 0.2 mL of saline were ip injected. 
Mice developed hemorrhagic ascites and diffuse peritoneal carcinomatosis and died by 15–30 days. 
Survival was the end point of the study and the median day of death (median survival time: MST) was 
calculated for each group. Antitumor activity was assessed as T/C%, that is, the ratio of MST in 
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treated over control mice x 100. Treatment started the day after tumor cell injection, delivering 2 ip 
every day for four days a week for two weeks (qdx4/wx2w) at a dose of 25 mg/kg. 
14. Determination of GGT activity 
 
Confluent cell monolayers were harvested with hypotonic lysis buffer (10mM Tris–HCl, pH 7.8) and 
disrupted by a tight-fitting glass–glass Dounce homogenizer (30 strokes, 4 ◦C). Determination of 
GGT activity was performed according to Huseby and Strømme [11] using γ-glutamyl-p-nitroanilide 
as substrate and glycylglycine as transpeptidation acceptor. The amounts of p-nitroaniline formed 
were measured by reading the absorbance at 405nm and using a molar extinction coefficient of 
9200mol/L cm. One unit of GGT activity was defined as 1µmol of substrate transformed/mL/min. 
The results were expressed as mU/mg protein. 
15. Reactive oxygen species (ROS) determination 
 
Intracellular production of ROS was measured using the H2O2-sensitive compound 2′, 7′-
dichlorofluorescin diacetate (DCFH-DA, Molecular Probes, Invitrogen Ltd, Paisley, UK). After 
diffusion into viable cells, DCFH-DA is converted by intracellular esterase to 2′, 7′-dichlorofluorescin 
(DCFH) which reacts quantitatively with ROS within the cell thus producing the fluorescent dye 2′, 
7′-dichlorofluorescin (DCF). The latter remains trapped within the cells and can be measured as an 
index of intracellular ROS production. Cells were seeded in Petri dishes (100,000 cells/ml) and 24 h 
after the 2 h treatment with H2O2, arsenic trioxide or/and ascorbic acid (depending on the assay, as 
explained in the Results section) cells were incubated with DCFH-DA (10 µM, in DMSO) at 37°C for 
20 min. Adherent and floating cells were collected and washed twice with phosphate-buffered saline 
(PBS). DCF fluorescence was detected using a flow cytometer (FACScan, Becton Dickinson, 
Franklin Lakes, NJ, USA); for each sample 10,000 events were collected. 
16. Determination of catalase activity 
 
The Amplex Red Catalase Assay Kit, used for the determination of catalase activity, was purchased 
from Molecular Probes (Invitrogen Ltd, Paisley, UK). In this assay, catalase first reacts with H2O2 to 
produce water and oxygen, then the Amplex Red reagent reacts with any unreacted H2O2 in the 
presence of horseradish peroxidase to produce the highly fluorescent oxidation product, resorufin. 
Catalase activity was determined 6 and 24 h after 2 h treatment. Briefly, cells were rinsed twice with 
ice-cold PBS containing 0.1 mM sodium orthovanadate and then lysed in hot sample buffer (0.125 M 
 Tris-HCL pH 6.8, 25 mM NaF, 1 mM phenyl-methyl-sulphonyl fluoride, 10 µg/ml trypsin inhibitor, 
10 µg/ml pepstatin, 5% sodium dodecyl sulphate, 12.5 µg/ml leupeptin and 100 kIU aprotinin) [6]. 
Catalase activity was determined spectrophotometrically (550 nm) according to manufacturer's 
instructions and data were normalized to total protein content. 
17. Cell cycle analysis 
 
For cell cycle analysis, cells were washed 24 h after drug treatment, fixed in ice-cold 70% ethanol, 
and stored at –20°C. Subsequently, samples were rehydratated with PBS and cellular DNA was 
stained with 10 µg/ml propidium iodide in PBS, containing ribonuclease A (RNase A) (66 kU/ml). 
Cell cycle distributionwas determined by flow cytometry and data were analyzed using the 
CellQuest® software (Becton Dickinson, Franklin Lakes, NJ, USA); for each sample 40,000 events 
were collected. 
18. Detection of BrdU incorporation in DNA synthesizing cells 
 
Twenty-four hours after drug exposure, cells were treated with 10 µM bromodeoxyuridine (BrdU) for 
1 h. Adherent cells were trypsinized and fixed in ice-cold ethanol 70%. Cells were then incubated 
with 2N HCl for 30 min and resuspended in 1 ml 0.1 M disodiumtetraborate (Na2B4O7*10H2O), for 
10 min. Following washing with PBA (PBS containing 1% bovine serum albumin) for 10 min, cells 
were incubated first with the anti-BrdU antibody (Becton Dickinson, Franklin Lakes, NJ, USA) for 30 
min and then with the anti-mouse IgG FITC (Sigma Chemical Co., St. Louis, MO, USA) for 30 min. 
Cells were washed twice in PBA and resuspended in 1 ml PBS containing propidium iodide (5 µg/ml) 
and RNase A (66 kU/ml). DNA content was then analyzed with a FACScan flow cytometer. 
19. Single-cell gel electrophoresis (comet assay) 
 
DNA damage was measured using the alkaline comet assay as described by Duarte et al. [12]. Briefly, 
cells were harvested by trypsinisation and suspended in 0.6% low melting point agarose. Eighty 
microliters of the agarose gel (containing approximately 104 cells) were dispensed onto glass 
microscope slides previously coated with 1% normal melting point agarose. The agarose was allowed 
to set on ice under a coverslip and the slides left overnight in ice-cold lysis buffer (100mM disodium 
EDTA, 2.5M NaCl, 10mM Trizma® base, adjusted to pH 10 with NaOH 10M and containing 1% 
Triton X-100 (v/v) added fresh). Slides were washed with distilledwater and then placed in a 
horizontal electrophoresis tank containing ice-cold alkaline electrophoresis solution (300mM NaOH, 
1mM disodium EDTA) for 20 min to allow DNA unwinding. Electrophoresis was conducted for 
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20min (30 V, 300mA) at 4 ◦C. Slides were neutralised with 0.4M Tris–HCl, pH 7.5 for 20 min and 
washed with double-distilled water, then allowed to dry. All procedures were carried out under 
subdued light to minimise background DNA damage. For staining, slideswere re-hydrated in distilled 
water, incubated with a freshly made solution of 2.5µg/mL propidium iodide for 20 min, washed 
again for 30 min and allowed to dry. Comets were visualised with a fluorescence microscope (Leica) 
at 200× magnification using a 20× objective. Images were captured by an on-line Leica DFC320 
camera and subsequently analyzed with the CometScoreTM software (TriTek Corporation). 
A total of 100 cells were analyzed per sample, 50 per duplicate slide. The percentage of DNA in the 
tail of the comet (% tail DNA) was calculated for each cell by the CometScoreTM software. 
20. Fpg-modified comet assay 
 
Oxidative DNA damage was evaluated by Fpg-modified comet assay as previously described [13]. 
This assay uses the formamidopyrimidine-DNA-glycosylase (Fpg) enzyme (New England Biolabs), a 
glycolase that recognizes and specifically cleaves the oxidized bases principally 8-oxoguanine from 
DNA, producing apurinic sites which are then converted into breaks by the associated AP-
endonuclease activity. These additional breaks can be detected by comet assay and give a measure of 
oxidative DNA damage. The comet assay was carried out as described above, with the exception that 
after lysis the slideswerewashed three times for 15 min with the enzyme reaction buffer (40mM 
HEPES, 0.1M KCl, 0.5mM EDTA, 0.2mg/mL bovine serum albumin, adjusted to pH 8 with KOH 1 
M). After this time, slides were incubated with 100 µL of Fpg enzyme. Enzyme dilution (1:103 from a 
stock solution of 8000 U/mL) was prepared just before use, according to the manufacturer’s 
instructions. Control slideswere treated with 100 µL of enzyme reaction buffer only. Slides were 
placed horizontally in humidity chamber at 37 ◦C for 45 min. DNA unwinding and electrophoresis 
was then performed as described above. 
21. Glucose uptake 
 
For determination of glucose uptake complete culture medium was replaced with Hanks’ buffer, pH 
7.4, containing 2µCi of 2-deoxy-D-[1-3H]glucose (Amersham Biosciences, UK), and cells were 
incubated for 30min at 37 ◦C in a 5%/95% CO2/air atmosphere. GLUT inhibitor cytochalasin B 
(20µM) was added to a subset of wells to determine specific carrier-mediated glucose uptake. The 
medium was then removed and the cells were washed twice with ice-cold PBS. Lysiswas induced by 
 adding 600µL of 0.1N NaOH. Aliquots of 450µL of lysates were then mixed with a liquid scintillator 
(Beckman Ready Safe cocktail) and the radioactivity was measured by liquid scintillation counting 
(Beckman LS-6500 Multi Purpose Scintillation counter). Finally, the remaining part of samples was 
used for determination of protein content. In a separate set of experiments, c21/GGT cells were pre-
treated for 24 h with GGT competitive inhibitor ABBA (20µM) before incubation with radiolabeled 
glucose. Data are expressed as glucose uptake in the absence of cytochalasin B minus uptake in the 
presence of cytochalasin B. 
22. Other determinations 
For GSH determinations, aliquots of incubation mixtures were collected, acidified with 5-
sulfosalicylic acid (1%, w/v) and stored to −20 ◦C until GSH determinations that were performed 
according to Baker et al. [14].  
23. Statistical analysis 
All the reported values represent the mean ± standard deviation (SD) of at least three independent 
experiments performed in duplicate. Where necessary, data were statistically compared by t test. 
More exhaustive statistical analysis of data was performed, were necessary, by ANOVA, with 
Newman–Keuls test for multiple comparison. 
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Results and Discussion 
 
          Section A: Hsp90 
 
            Chapter A1: Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
During a target-oriented screening of natural compounds aimed at stabilizing and enhancing the 
function of p53, a transcription factor which regulates the cell cycle and thus functions as a tumor 
suppressor, we found that a fungal metabolite, named bulgarialactone B (2), did not change the wild-
type p53 protein level but induced partial down-regulation of the mutant p53, which is known to be 
stabilized by Hsp90. This result prompted us to investigate the activity of bulgarialactone B as a 
potential Hsp90 inhibitor. Structurally, bulgarialactone B features a highly oxygenated tricyclic core 
linked to a 13-C unsaturated chain containing a β-diketone. It is a member of a large group of fungal 
pigments known as azaphilones, mainly isolated from perfect and imperfect stages of Ascomycetes, 
such as Aspergillus, Penicillium, Hypoxylon, and Monascus spp. 
As a first step of this study, we investigated the cellular and biochemical profile of compound 2. 
The antiproliferative assays were performed on a panel of human tumor cell lines following 72 h 
exposure. The IC50 values of 2, reported in Table 1, indicated variable antiproliferative effects on the 
tested cell lines in a range of micromolar concentrations. 
Successively, compound 2 was tested for its effects on Hsp90 client protein expression in the same 
cell lines used in the antiproliferative assay (Fig. 1). Following 24-h exposure to a concentration 
corresponding to IC80 (around 2 X IC50; i.e., ca. 10 µM), the examined client proteins (Raf-1, 
 Figure 1. Analysis of Hsp90 client protein levels (survivin, Cdk4, Akt, 
Raf-1) in  tumor  cells treated with (2). Total cellular extracts were 
obtained 24 h after treatment (11 µM, IC80). Actin is shown as a control 
for protein loading. EGFR levels were analyzed only in A431 cells and 
tubulin is shown as a control for protein loading. 
survivin, Cdk4, Akt, and EGFR) were down-regulated. The effect was marginal in melanoma JR8 
cells. In contrast, protein depletion was almost complete in the ovarian carcinoma cell line, IGROV-1. 
The p53 protein was partially down-regulated only in A431 cells carrying a mutant p53 protein. This 
effect was consistent with the stabilization of the mutant form by Hsp90. 
 
 
In an effort to confirm the Hsp90/compound 2 binding and to identify the binding site, we used 
surface plasmon resonance (SPR) analyses and the limited proteolysis–mass spectrometry technique. 
SPR allows verifying the affinity of compounds toward the protein, and to assess how they associate 
with and dissociate from the protein in real time, giving a more detailed view of their interaction with 
Hsp90. SPR experiments were performed using radicicol (Chart 1), a well-known Hsp90 inhibitor, as 
a positive control. Our data demonstrated the high affinity of 2 for Hsp90, comparable with that 
measured for radicicol (Table 2), both in terms of thermodynamic (KD) and kinetic (kd) dissociation 
constants. The limited proteolysis approach is based on the evidence that exposed, weakly structured, 
and flexible regions of a protein can be recognized by a proteolytic enzyme. Trypsin, chymotrypsin, 
and endoprotease V8 were selected as conformational probes in order to provide structural 
information on different regions of Hsp90. The fragments released from the protein were identified by 
MALDI-TOF/MS analyses, leading to the assignment of cleavage sites (Table 2).  
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The differences in the proteolytic patterns were analyzed to identify the protein regions involved in 
the molecular interactions. In Figure 2A, the preferentially hydrolyzed positions observed on isolated 
Hsp90 are shown: widespread cleavage sites within the entire protein structure have been identified. 
Comparing our data with the predicted secondary structure organization of Hsp90, it can be deduced 
that most of the identified cleavage sites are located in unstructured portions, thus confirming the 
efficiency of the approach. To further validate the method, the radicicol/Hsp90 complex was 
investigated, since the radicicol binding region has been deeply characterized by crystallography.The 
results achieved in the radicicol/Hsp90 complex are shown in Figure 2B. Comparison between the 
proteolysis patterns observed on Hsp90 with or without radicicol indicates significant protection of 
the N-terminal domain from enzymatic hydrolysis. This result is in agreement with the 
radicicol/Hsp90 interaction involving the ATPase located in the N-terminal domain of Hsp90. Limited 
proteolysis analysis of the compound 2/Hsp90 complex produced the fragmentation pattern 
summarized in Figure 2C. These data demonstrate that most of the N-terminal domain sites as well as 
those located in the protein portion interconnecting this domain to the middle domain were protected 
following complex formation, thus suggesting an interaction involving the 90–280 region of Hsp90.  
 
 
 
Figure 2. Schematic representation of the results obtained 
from limited proteolysis experiments on recombinant 
Hsp90. The preferential cleavage sites detected performing 
enzymatic digestions on recombinant Hsp90 (A), on the 
Hsp90/radicicol complex (B), or on the Hsp90/compound 
2 complex (C), are in dark gray. The Hsp90 N-terminal 
domain is highlighted in light gray, the middle domain is 
boxed and the C-terminal domain is highlighted in gray. 
Figure 3. (A) Analysis of Hsp90 client protein levels and Hsp70 
in A431 cells. Total cellular extracts were obtained 24 h after 
treatment (11 µM, IC80). Actin is shown as a control for protein 
loading. EGFR levels were analyzed only in A431 cells and 
tubulin is shown as a control for protein loading. 
(B) Coimmunoprecipitation of Raf-1/Hsp90 4 h after 17-AAG or 
(2) treatment, in A431 cells. Cells were treated with equitoxic 
(IC80) concentrations of 17AAG (0.1 µM) or 2 (11 µM). Cell 
lysates were than harvested and immunoprecipitated with anti-
Raf-1 rabbit polyclonal antibody. Immunoprecipitates were 
immunoblotted  for Hsp90 Blots were stripped and probed for 
Raf-1. 
 In contrast to the effects of ansamycin inhibitors of Hsp90 (e.g., 17AAG), compound 2 did not induce 
up-regulation of Hsp70. The lack of modulation of Hsp70 could reflect a different binding mode of 2 
to Hsp90, which did not involve the shift of client association from Hsp90 to Hsp70 prior to 
proteasome-mediated degradation. In A431 cells treated with 2 for 4 h, a coimmunoprecipitation 
experiment performed with anti-Raf-1 antibody revealed a reduced amount of Hsp90 bound to the 
client protein, as could be expected from an Hsp90 inhibitor (Fig. 3A). The effect was comparable to 
that of 17AAG at equitoxic concentrations. However, this short treatment did not induce a shift of the 
binding of Raf-1 from Hsp90 to Hsp70, because the level of coprecipitated Hsp70 with Raf-1 was 
undetectable (Fig. 3B). The lack of up-regulation of Hsp70 in treated cells has been observed with 
other putative inhibitors of Hsp90 (e.g., epigallocatechin [15] and curcumin [16]). 
This finding would suggest a mechanism of interaction different from that of geldanamycins, that 
target the ATP-binding site of Hsp90. This interpretation was also supported by proteolysis 
experiments (Fig. 2). If interaction with other cochaperones contributes to the modulation of Hsp90 
function by the novel agents remains to be explored. 
In the above experiments, aimed at a biochemical analysis of protein expression modulation (Fig. 1), 
the exposure time was only 24 h, because prolonged exposure resulted in the partial detachment of 
cells. Indeed, at 48 h, marked cleavage of poly (ADPribose) polymerase and activation of caspase-3 
were found in cells treated with 2, supporting apoptosis induction (Fig. 4).  
 
The promising results obtained by testing compound 2 prompted us to investigate the activity of other 
azaphilones as potential Hsp90 inhibitors. We therefore tested the natural compounds 1–13 for their 
cytotoxic activity against a variety of human tumor cell lines; they were also tested for their ability to 
inhibit Hsp90 ATPase activity and for binding affinity in the FP assay (Table 1). The most potent 
compounds of this series were 1, 2, and 5, characterized by IC50 values ≤10 µM against several cell 
lines. The potency of these compounds was substantially lower than that of geldanamycin or its 
analogue 17-AAG (IC50 in A431 cells, 0.2 ± 0.04 and 0.07 ± 0.01 µM, respectively). In the case of 
compound 2, the reduced potency was consistent with a low affinity for Hsp90 in the competitive 
Figure 4 Biochemical analysis of apoptosis-related factors 
in IGROV-1 cells. 
Cleaved Caspase-3 and PARP-1 expression levels were 
analyzed by Western blot and total cellular extracts, used 
for this analysis, were obtained both 24 h and  48 h after 
treatment with 2 (11 µM). 
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binding assay (IC50 61.7 ± 0.85 vs 1.095 ± 0.05 for 17AAG). Interestingly, the two pyranyl 
compounds 8 and 9, with a saturated side-chain, exhibited strong binding to Hsp90. This was 
paralleled by the twofold increase of binding going from 2 to 5. However, this strong binding was not 
reflected in the antiproliferative potency. A plausible explanation for this discrepancy could be the 
unfavorable cellular pharmacokinetics. The series of natural deflectins (10–13), characterized by an 
angular lactone fused to a dihydroisochromenone ring, were found to be almost inactive. In an attempt 
to identify the structural requirements involved in the Hsp90 inhibitory activity, the semisynthetic 
compounds 14–19 were prepared exploiting the well-known reactivity of azaphilones with amines. 
The IC50 values of compounds 14–19, reported in Table 3, indicated that these agents were generally 
more potent than compounds of the previous series (1–13). 
 
Among the open-ring analogues (14a–e), compound 14a, containing a benzyl substituent on the 
nitrogen, was the most potent in the antiproliferative assay. These compounds showed moderate 
binding to Hsp90, comparable to that of 2. On the contrary, compounds 16 and 17, containing the 
same tricyclic system and the same benzyl substituent on N-7, exhibited increased Hsp90 binding, the 
highest value (IC50 4 nM) being shown by the monascorubrin derivative 17. Figure 5 shows the 
analysis of client protein expression modulation.  
  
The effects on the examined proteins were variable among cell lines. Compounds 14a and 14d caused 
marked depletion of Raf-1 and Akt in IGROV-1 and JR8 cells (Fig. 5A). In contrast to the marginal 
effect of 2, compounds 14a, 14d, 15, and 17 were very effective in causing depletion of client proteins 
in JR8 cells (Fig. 5A and B). Compound 14d caused almost complete depletion of EGFR in A431 
(Fig. 5A). The effects of 14a and 16 on EGFR expression in A431 cells were less marked at equitoxic 
concentrations (IC80) (Fig. 5A and C). For compound 14a, coimmunoprecipitation with anti-Raf-1 
antibody, performed after 4-h exposure, revealed reduced binding of Raf-1 to Hsp90 (not shown). 
However, the depletion was dose dependent and the variable effects on the client protein levels were 
likely determined by the relative sensitivity of the various cell lines (Fig. 6). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparison of biochemical effects on Hsp90 client proteins. (A) 
Hsp90 client expression levels after 24 h treatment with (14a) or (14d). Total 
cellular extracts were obtained 24 h after treatment with equitoxic (IC80) doses of 
(14a, 2.7 µM for A431 cells; 10.7 µM for JR8 cells, 2.3 µM for IGROV-1 and 
11.6 µM for STO cells) or (14d, 8.6 µM for A431; IGROV-1 and STO cells; 16 
µM for JR8 cells). Actin is shown as a control for protein loading. (B) Hsp90 
client expression levels after 24 h treatment with (17) or (5) in JR8 cells. Total 
cellular extracts were obtained 24 h after treatment with equitoxic (IC80) doses of 
(17, 6.36 µM) or (5, 9.3 µM). Actin is shown as a control for protein loading. (C) 
Hsp90 client expression levels after 24 h treatment with (16). Total cellular 
extracts were obtained 24 h after treatment (16, 9.8 µM, IC80). Actin is shown as 
a control for protein loading. 
Figure  6. Dose–response of the biochemical effect 
of (2) and (14a) on Hsp90 client proteins in A431 
cells.  
Total cellular extracts were obtained 24 h after 
treatment with (2) (4.4, 11, 22 µM) or (14a) (0.3, 
2.32, 8.93 µM). Protein expression levels of EGFR, 
Akt, Cdk4 and survivin were analyzed by Western 
blot. The quantification of Western blot analyses 
was obtained with the Image Quant 5.2 software 
and results (relative expression normalized to the 
tubulin, as loading control) are presented as % of 
protein expression, as compared to the control. IC50 
values of the down-regulation of each protein level 
are reported in the plots. 
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Figure  8. Effect of 2 on survival of mice bearing ip ovarian carcinoma 
tumor IGROV-1. (s) Control mice; (d) mice treated ip daily with 2 (25 
mg/kg) for 4 days/week for 2 weeks. 
Compound 17 shows a strong binding to the enzyme (FP test), confirmed by the SPR analysis (KD 
47.8 ± 0.5 nM). However, the limited proteolysis experiment for 17 (Fig. 7) indicates a pattern similar 
to that of control, that is, no protection of the sensitive regions.                              
Figure  7 
 
 
 
 
It is therefore possible that compound 17 interacts with the protein in rather rigid regions (beta leaflets 
or, more likely, helical regions), about which the limited proteolysis approach cannot give enough 
information. Again, the deflectin derivative 19 showed no appreciable Hsp90 binding, like the parent 
natural compounds, thus confirming the detrimental effect of an angular structure. The lack of close 
correlation between affinity for Hsp90, as determined in the FP assay, and cellular effects, in terms of 
cell growth inhibition and of client protein depletion, could reflect an unfavorable cellular 
pharmacokinetics or interaction with other proteins which may limit the Hsp90 binding inside the cell. 
Indeed, the compounds related to bulgarialactone (e.g., 9 and 17) are characterized by a reactive 
conjugate system that could react with amines and thiols, present at high concentrations inside the cell 
(e.g., GSH). Preliminary in vivo antitumor activity studies supported the therapeutic potential of this 
new series of compounds. In particular, intraperitoneal administration of 2 to athymic nude mice 
bearing ovarian carcinoma xenografts growing intraperitoneally as ascitic tumors resulted in a 
substantial increase in survival (Fig. 8).  
         
 
 
 
 
 
 Chapter   A2: The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors 
by curcumin is mediated by Hsp90 inhibition 
 
A2.1: Down-regulation of Hsp90 client proteins by curcumin 
The analysis of protein expression was performed in two cell lines, the squamous cell carcinoma 
A431 and mesothelioma STO cells after 24 h-exposure to IC80 of curcumin (5 µM). The two cell 
lines exhibited a comparable sensitivity to curcumin in the anti-proliferative assay Curcumin and 
HDAC inhibitors (Fig. 1). 
                        
 As shown in Fig. 2a, EGFR, Raf-1, Survivin, and Cdk4 protein expression were strongly 
downregulated by curcumin treatment, whereas the effect was less marked for Akt. This effect was 
consistent with previous observations indicating a delayed depletion of Akt produced by other Hsp90 
inhibitors [17].  
 
 
Fig. 1 Antiproliferative effect of curcumin on A431 and 
STO cells. Cells were treated for 72 h with curcumin and 
cell growth was evaluated 72 h after the treatment by cell 
counting. Inverted filled triangle A431 cells (IC50, 2.2 µM); 
open circle STO cells (IC50,2.1 µM). Data are the mean of 
three independent experiments 
Fig. 2 a Effect of curcumin on Hsp90 client protein levels in A431 
and STO cells. Total cellular extracts were obtained 24 h after 
treatment with curcumin (5 µM, IC80). Actin is shown as a control for 
protein loading. C Control, CUR curcumin. b Comparison of the 
effects of curcumin and 17-AAG on protein levels of Hsp70. Cells 
were treated as described in (a), with curcumin (5 µM) or 17-AAG 
(0.1 µM). c Coimmunoprecipitation of Raf-1/Hsp90 in A431 cells 
treated with 17-AAG or curcumin for 1 h. Cells were treated with 
equitoxic concentrations of 17-AAG (0.1 µM, IC80) or curcumin (5 
µM). Cell lysates were than harvested and immunoprecipitated with 
anti-Raf-1 rabbit polyclonal antibody. Immunoprecipitates were 
immunoblotted for Hsp90. Blots were stripped and probed for Raf-1. 
C Control, AAG 17-AAG, CUR curcumin. d Coimmunoprecipitation 
of Hsp90/hsc70 and Hsp90/p23 in A431 cells treated with curcumin. 
Cells were treated with two concentrations of curcumin (2 and 5 µM; 
i.e., IC50 and IC80) as described above. Immunoprecipitated obtained 
by anti-Hsp90 antibody were immunoblotted for hsc70 or p23. C 
Control, CUR2 curcumin 2 µM, CUR5 curcumin 5 µM. e Effect of 
bortezomib (BOR) on the depletion of Hsp90 client proteins induced 
by curcumin (CUR) in A431 cells. Total cellular extracts were 
obtained 24 h after treatment (curcumin 5 µM, bortezomib 0.001 
µM). Actin is shown as a control for protein loading. C Control 
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However, in contrast to the geldanamycin derivative, 17-AAG, curcumin did not cause increased 
expression of Hsp70 (Fig. 2b). To investigate the mechanism of down-regulation of Hsp90 clients, co-
immunoprecipitation of Raf-1/Hsp90 was performed in A431 cells. After 4 h exposure to curcumin (5 
µM) or equitoxic concentration of 17-AAG (0.1 µM), a lower amount of Hsp90 was found in complex 
with Raf-1 (Fig. 2c). Thus, in spite of a different potency, the effects of the two agents were 
comparable at equitoxic concentrations. An additional characterization of the effect of curcumin on 
the association between Hsp90 and cochaperones was performed in an immunoprecipitation assay 
with anti-Hsp90 antibody (Fig. 2d). The results showed that anti-proliferative concentrations of 
curcumin reduced the interaction of Hsc70 (but not of p23) with Hsp90. The inhibition of Hsp90–
client interaction is expected to result in client protein degradation mediated by the ubiquitin–
proteasome system [18, 19]. The combination of bortezomib, a well-known proteasome inhibitor, 
with curcumin prevented protein depletion induced by curcumin (Fig. 2e), thus supporting that the 
observed curcumin-induced protein down-regulation occurred via the ubiquitin–proteasome pathway. 
A2.2: Curcumin-Hsp90 interaction 
The competitive binding fluorescence polarization assay gave an IC50 of 6.2 ± 0.12 lM for curcumin, 
1.09 ± 0.05 lM for 17-AAG, and 0.058 ± 0.001 for radicicol. Thus, the different anti-proliferative 
potencies of curcumin and 17-AAG (IC50 values, 2.4 and 0.06 µM, respectively) were consistent with 
their binding affinities to Hsp90. We used the limited proteolysis–mass spectrometry technique for the 
structural analysis of drug–Hsp90 interaction [20]. This approach is based on the evidence that 
exposed, weakly structured, and flexible regions of a protein can be recognized by a proteolytic 
enzyme. The differences in the proteolytic patterns occurring on the protein when it underwent 
digestion in the presence or in the absence of putative ligands allow identification of the protein 
regions involved in the molecular interactions [21]. Results achieved in the experiment performed on 
Hsp90, on the Hsp90/curcumin complex, and on the Hsp90/radicicol complex are summarized in Fig. 
3 and in Table 1.  
 
 
  
 
A comparison between the proteolysis patterns observed on free Hsp90 and Hsp90/curcumin complex 
demonstrated that the sites 94, 215, and 245, cleaved in the experiments performed on the isolated 
proteins, were protected following the complex formation, thus suggesting an interaction involving 
the Hsp90 N-terminal domain. However, binding of the protein with curcumin also produced an 
higher susceptibility to enzymatic hydrolysis of same sites located into the middle domain, suggesting 
a possible long-range effect of the curcumin on the protein tertiary structure. The experiments 
performed on the Hsp90/radicicol complex indicated a significant protection of the N-terminal 
domain from enzymatic hydrolysis. This result is in agreement with the radicicol/Hsp90 interaction  
involving the ATPase portion located into the N-terminal domain of Hsp90 [22]. We used surface 
plasmon resonance to measure kinetic and thermodynamic parameters of ligand–protein complex 
formation [23]. An SPR-based binding assay as implemented with Biacore technology was, therefore, 
used to investigate the drug–protein interactions. The values of the constants (Table 1) indicated that 
curcumin exhibited an high affinity for Hsp90, even if it was lower than that measured for radicicol. 
However, the difference in the thermodynamic dissociation constants (KD) observed for these two 
compounds mainly depend on the stability of the respective protein complexes, as inferred by the 
lower kinetic constant (Kd) determined for curcumin in respect of that of radicicol. 
 
A2.3: Cellular effect of the combination of curcumin with HDAC inhibitors 
In combination studies, we used vorinostat and panobinostat, two hydroxamic acid-based compounds, 
which are well-known pan-histone deacetylase inhibitors including HDAC6. The cell growth 
inhibition studies were performed using subtoxic concentrations of curcumin (IC10–20) (Fig. 4). 
Fig. 3 Schematic representation of the 
results obtained from limited proteolysis 
experiments on recombinant Hsp90. The 
preferential cleavage sites detected 
performing enzymatic digestions on 
recombinant Hsp90, on the Hsp90/curcumin 
complex, and on the Hsp90/radicicol 
complex are in dark grey. The Hsp90 N-
terminal domain is highlighted in light grey, 
the middle domain is boxed and the 
C-terminal domain is highlighted in grey 
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Under these conditions, the combined treatment resulted in a marked enhancement of the anti-
proliferative activity of either vorinostat or panobinostat as shown by the dose response curves. Based 
on these observations, further experiments of drug interaction were performed with subtoxic 
concentrations of all agents (IC20), i.e. curcumin (1.5 µM), panobinostat (11.5 nM), and vorinostat 
(15 nM). Apoptosis response was examined after 72 h exposure by TUNEL analysis (Fig. 5a).  
 
When tested at these concentrations, single drug treatment induced only a marginal extent of 
apoptosis, whereas the combination treatment markedly enhanced apoptotic response to around 50%. 
A similar enhancement was observed following a shorter exposure (24 h) and 72 h incubation in drug-
free medium. On the contrary, when apoptosis was assessed after 72 h exposure to cytotoxic 
concentrations of single drug (IC80), a consistent number of apoptotic cells was found; but the shorter 
exposure followed by drug removal, indicated the reversibility of the effect of these agents, as no 
significant apoptosis was found (Fig. 5b). These results confirm that, differently from single 
treatment, the sensitization resulting from the drug interaction did not require prolonged exposure, 
suggesting an irreversible effect specific of the combined treatment. 
 
A2.4: Effect of the combination of curcumin and HDAC inibitors on levels of Hsp90 client proteins 
In order to investigate the molecular basis of the synergistic interaction between curcumin and HDAC 
inhibitors, the effects of single agents and their combination on Hsp90 client proteins were examined 
by western blot analysis using the same (subtoxic) concentrations of previous experiments.  
 
 
Fig. 5 a Effect of curcumin on apoptosis induced by HDAC 
inhibitors in A431 cells. Cells were exposed for 72 h to subtoxic 
concentrations of panobinostat (11.5 nM) or vorinostat (15 nM), 
alone or in combination with curcumin (1.5 µM). b Apoptotic cell 
death caused by cytotoxic concentrations of single agent treatment. 
Cells were exposed for 72 h to cytotoxic concentrations of 
panobinostat (100 nM), vorinostat (1 µM) and curcumin (5 µM). At 
the end of the treatment, apoptosis was detected by TUNEL assay 
and determined by FACS analysis. In a parallel experiment, cells 
were treated for 24 h and apoptosis was detected after 72 h following 
drug removal. Data from three independent assays were analyzed by t 
test (control vs treatment): *P≤0.05, **P≤0.005 
  
Figure 6 shows that, under these conditions, single agents did not produce appreciable changes of 
protein expression. In contrast, the combinations of curcumin with either HDAC inhibitors caused 
depletion of the well-established client proteins, in particular Akt, EGFR, and Raf-1. The 
downregulation of Cdk4 and survivin was less marked and may reflect a different kinetics of 
depletion as suggested by the effect of the combination on survivin 24 h after treatment. 
The reduction of the Hsp90 client protein levels was persistent even 24 h after drug removal, with the 
exception of Cdk4. The persistence of the client down-regulation was typical of the combined 
treatments; indeed, when cells were treated with single agents (IC80) and incubated in drug-free 
medium for 24 h, the biochemical effects were lost (Fig. 6c). 
To better document the involvement of Hsp90 inhibition in down-regulation of client proteins, we 
have performed a coimmunoprecipitation analysis after 4 h exposure, i.e. under conditions where a 
substantial depletion of client proteins is not expected (Fig. 7).  
 
Fig. 6 Effects of combination of curcumin/vorinostat (a) or 
curcumin/panabinostat (b), or single agent treatment (c) on 
cellular levels of Hsp90 client proteins. a,b Cells were exposed 
to each drug alone or in combination for 24 h and processed as 
indicated in legend to Fig. 2. 
Subtoxic concentrations of each drug were used (i.e. curcumin 
1.5 µM, vorinostat 15 nM, panobinostat 11.5 nM). The analysis 
was also performed after incubation of the drug-treated cells in 
drug-free medium for 24 h. c Cells were exposed to cytotoxic 
concentrations (IC80) of each drug (i.e. curcumin 5 µM, 
vorinostat 1 µM, panobinostat 0.1 µM) for 24 h and processed 
as indicated in the legend to Fig. 2. The analysis was also 
performed after incubation of the drug-treated cells in drug-free 
medium for 24 h. Actin is shown as a control for protein loading 
Fig. 7 Coimmunoprecipitation of Raf-1/Hsp90 in A431 cells treated 
with curcumin, vorinostat, panobinostat alone or in combination. 
A431 cells were exposed to subtoxic concentrations of panobinostat 
(11.5 nM), vorinostat (15 nM), and curcumin (1.5 µM) alone or in 
combination, for 4 h. Cell lysates were than harvested and 
immunoprecipitatedwith anti-Raf-1 rabbit polyclonal antibody. 
Immunoprecipitates were immunoblotted for Raf-1. Blotswere 
stripped and probed for Hsp90 and Hsp70 
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Again in contrast to a negligible effect of single agents, the combination treatment reduced the 
amount of Hsp90 bound to Raf-1, an effect most evident with the combination of curcumin and 
vorinostat. This observation was consistent with an enhanced inhibition of Hsp90 function, resulting 
in a reduced association of Hsp90 with Raf-1. The combined treatment resulted in a concomitant 
increase in the binding of Raf-1 to Hsp70. The shift of the binding from Hsp90 to Hsp70 has been 
described as an event preceding proteasome-mediated degradation of the client proteins [24, 25, and 
26]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Section B: GGT 
Chapter B1: Cellular response to oxidative stress and ascorbic acid in melanoma cells 
overexpressing γ- glutamyltransferase 
 
B1.1: Biochemical characterisation of cell clones 
 
The study was performed on two human melanoma clones, characterised by a marked difference in 
GGT activity (Table 1), the c21/GGT clone exhibiting a high GGT activity (90.8 ± 3.4 mU/mg 
protein), in contrast to the low activity of the c21/basal clone (approx. 180 times lower). In spite of the 
substantial difference in GGT activity and expression (not shown), the GSH content was marginally 
higher in the c21/basal clone. Interestingly, the content of GSSG was appreciably increased in the 
GGT-overexpressing clone and the increased GSSG/GSH ratio supports conditions of oxidative 
stress. Cell doubling time was not modified by transfection procedures, and was approximately 24 h 
in both clones. 
 
B1.2: Cell response to H2O2-induced oxidative stress 
We have investigated whether the overexpression of GGT could influence the antiproliferative 
activity of hydrogen peroxide. The effects of H2O2 were investigated both in standard cell culture 
conditions and in medium supplemented with GSH (500 µM) and glycyl-glycine (20 mM), in order to 
achieve full activation of GGT.6 As shown in Fig. 1, when cells were exposed for 2 h to hydrogen 
peroxide under standard conditions, a different response was observed, with an IC50 value for 
c21/GGT cells (2.3 mM) about 50 times higher than that observed for c21/basal cells (0.05 mM). 
Similar differences were observed when clones were exposed to H2O2 in conditions of full GGT 
activation (data not shown). On the basis of these results, two equitoxic hydrogen peroxide 
concentrations (4.6 mM and 100 µM for c21/GGT and c21/basal clone, respectively, causing approx. 
70% inhibition of cell growth in standard culture medium) were chosen for subsequent experiments. 
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B1.3: Effects of H2O2 on intracellular ROS production 
Analysis of ROS production was performed 24 h after the end of H2O2 treatment. As shown in Fig. 2, 
in spite of the higher concentration of H2O2 applied, in the c21/GGT clone the extent of intracellular 
ROS production was lower than in c21/basal cells. 
 
 
B1.4: Effects of H2O2 on cell cycle 
As shown in Fig. 3, equitoxic concentrations of H2O2 caused different effects on cell cycle 
distribution in the two clones. 24 h after a 2 h-exposure to H2O2, an accumulation in G2 phase was 
observed for c21/GGT cells, while the c21/basal clone showed an arrest in S phase concomitant with a 
decreased percentage of cells in G1 phase. 
 
Fig. 1 – Cytotoxic effect of H2O2 on c21/GGT 
and c21/basal clone. Cells were treated for 2 h 
with H2O2 and cell viability was evaluated 72 h 
after the treatment by cell counting. Data are the 
mean of three independent experiments. 
Fig. 2 – ROS induction 24 h after a 2 
h H2O2 exposure. Cells treated with 
H2O2 (4.6 mM and 100 µM for 
c21/GGT and c21/basal clone, 
respectively) were incubated with 10 
µmol/L DCFH-DA. The DCF 
fluorescence was detected by 
FACScan flow cytofluorimeter. One 
representative experiment out of three 
was reported. The percentages of 
DCF-positive cells 
 
  
To elucidate the reasons for the differences observed, we examined the activation of three selected 
proteins involved in DNA damage/repair response, i.e. histone γ–H2AX, phospho-p53 (Ser15) and 
RPA-2. As assessed by western blot analysis (Fig. 4), exposure to equitoxic concentrations of H2O2 
induced a higher induction of γ–H2AX phosphorylation and phospho-p53 (Ser15) in c21/basal than in 
c21/GGT cells, whereas RPA-2 was not activated in either clones. 
 
 
B1.5: Effects of ascorbic acid on cell proliferation 
Exposure to AA for 2 h was able to exert an antiproliferative effect, which was two times higher in 
c21/basal than in c21/GGT cells (Fig. 5).  
 
 
 
 
Fig. 3 – Cell cycle distribution after H2O2 
exposure. Cells treated with the same 
equitoxic concentrations of H2O2 used for 
ROS induction analyses were examined 
for cell cycle distribution 24 h after the 
end of treatment. The percentages of cells 
in G1, S or G2 phases are reported in each 
histogram. 
Fig. 4 – Induction of DNA damage response 
in c21/GGT and c21/basal cells exposed to 
equitoxic H2O2 concentration for 2 h. After 
24 h from the end of treatment, cells were 
lysed and processed for Western blotting.  
1 = control, 2 = H2O2 treatment (4.6 mM for 
c21/GGT and 100 µM for c21/basal clone). 
Loading control is shown by actin. 
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Again, the differences observed between the two clones were similar in standard culture conditions 
and in the medium enriched with GSH and glycyl-glycine to activate GGT, even if in the latter 
condition AA citotoxicity was higher (Table 2). 
 
 On the basis of these results, two equitoxic concentrations of AA (0.06 mM and 0.03 mM for 
c21/GGT and c21/basal, respectively, causing approximately 30% inhibition of cell growth in GGT 
activating condition) were chosen for subsequent experiments. 
 
B1.6: Iron-mediated antiproliferative effects of H2O2 and ascorbic acid 
The involvement of redox-active iron in oxidative stress processes is a well established mechanism. 
To explore the possible role of iron in H2O2 and AA cytotoxicity, we evaluated the cellular response 
to these oxidative agents after lowering extra- and/or intracellular free (ionic) iron concentrations. In 
order to remove extracellular iron, incubation mixtures were pre-treated with the iron chelator DFO, 1 
h at 37 °C, before cell treatments. As shown in Fig. 6A-B, pre-treatment with DFO resulted in a 
reduced antiproliferative activity of H2O2 and AA in both clones.  
 
 
 
Fig. 5 – Antiproliferative effect of ascorbic acid. Dose 
dependent effect 72 h after a 2 h ascorbic acid treatment of 
c21/GGT and c21/basal cells, in GGT activating condition. 
Data are the mean of three independent experiments. 
  
 
Interestingly, when the same incubation mixtures were pre-treated with bipyridyl, an iron chelator 
capable of entering the cell and chelating both extra- and intracellular free iron, the antiproliferative 
effect of H2O2 and AA was almost completely prevented (Fig. 7A-B).  
 
The crucial role played by redox-active iron was further confirmed in experiments carried out at 
equimolar concentrations of AA. Indeed, in the presence of bipyridyl the sensitivity of c21/basal cells 
to AA was markedly reduced, down to a value similar to that observed in c21/GGT cells (from 65% to 
40% dead cells, Fig. 8A). 
 
Fig. 6 – Cellular sensitivity of c21/GGT (A) and 
c21/basal (B) cells to H2O2 and ascorbic acid in the 
presence or absence of DFO. Cells were treated for 2 h 
with a medium pre-incubated with ascorbic acid or H2O2 
in the presence/absence of DFO (500 µM; 1 h, 37 °C).  
1 = control; 2 = H2O2 (4.6mM and 100 µM for c21/GGT 
and c21/basal, respectively); 3 = AA (0.06 mM and 0.03 
mM for c21/GGT and c21/basal, respectively). 
Fig. 7 – Cellular sensitivity of c21/GGT (A) and c21/basal 
(B) cells to H2O2 and ascorbic acid in the presence or 
absence of bipyridyl (BIP). Cells were treated for 2 h with a 
medium preincubated with ascorbic acid or H2O2 in the 
presence/absence of bipyridyl (500 µM; 1 h, 37 °C). 1 = 
control; 2 = H2O2 (4.6mM and 100 µM for c21/GGTand 
c21/basal, respectively); 3 = AA (0.06 mM and 0.03 mM for 
c21/GGT and c21/basal, respectively). 
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B1.7: Suppression of AA antiproliferative effects by exogenous catalase 
Further experiments were performed to assess the involvement of hydrogen peroxide in AA 
antiproliferative effect. As shown in Fig. 8B, after pre-treatment with catalase (200 U/ml, 1 h, 37 °C) 
sensitivity to AA was significantly reduced in both clones, and the difference between clones was 
abolished. 
 
B1.8: AA treatment causes induction of apoptosis and ROS production 
Fig. 9 shows the results obtained with TUNEL assay 72 h after treating clones for 2 h with equitoxic 
concentration of AA. Ascorbic acid was able to cause a marked apoptotic cell death in c21/basal clone 
(27% TUNEL positive cells) while no appreciable effect was detectable in c21/GGT cells (3% 
TUNEL positive cells). Deeper analysis of the apoptotic behaviour of the two clones showed that 
cytochrome c release was induced by AA treatment in both clones (Fig. 10A), whereas cleavage of 
CPP32 was detectable only in c21/basal clone (Fig. 10B). No differences were observed either for 
Bax or Bcl-2 protein levels (Fig. 10B). Fig. 11 shows intracellular ROS induction in the two clones 
under the same experimental conditions used in TUNEL assay. DCF fluorescence induced by AA in 
c21/basal was at least six times higher than in c21/GGT cells. 
 
 
 
 
Fig. 8 – Cellular sensitivity of c21/GGT and c21/basal clone 
to ascorbic acid 0.06 mM in the presence or absence of 
bipyridyl (BIP) (A) or in the presence or absence of catalase 
200 U/ml (B). (A) Cells were treated for 2 h with a medium 
pre-incubated with ascorbic acid (equimolar concentration, 
0.06 mM) in the presence/absence of bipyridyl (500 µM; 1 
h, 37 °C). 1 = control; 2 = AA 0.06 mM; 3 = AA (0.06mM 
in the presence of bipyridyl 500 µM). (B) Cells were treated 
with a medium containing ascorbic acid (equimolar 
concentration, 0.06 mM) or ascorbic acid and catalase 200 
U/ml. 1 = control; 2 = AA 0.06 mM and 3 = AA (0.06 mM 
in the presence of catalase 200 U/ml). 
  
 
 
 
 
 
 
 
B1.9: AA treatment activates DNA damage response and cell cycle arrest 
DNA damage and cell cycle progression were investigated 24 h after AA treatment. The results 
showed an activation of DNA-damage responsive histone γ-H2AX and phospho-p53 (Ser15), which 
was more marked in c21/basal cells (Fig. 12). Cell cycle analysis indicated an accumulation of both 
clones in S phase (Table 3), suggesting the activation of a DNA damage checkpoint. 
 
 
Fig. 9 – Apoptosis induced by ascorbic acid. Cells 
were exposed for 2 h to 0.06 mM and 0.03 mM 
ascorbic acid corresponding to equitoxic value in 
c21/GGT and c21/basal cells, respectively. 
Apoptosis was detected by TUNEL assay 72 h after 
the end of the treatment and determined by FACS 
analysis. Numbers in the dot-plots indicate the 
percentage of  Tunel positive cells. 
Fig. 10 – Effect of ascorbic acid treatment on the apoptotic pathway. (A) 
Effect of ascorbic acid on cytochrome C release. 
The two cell lines were exposed to equitoxic concentration of ascorbic acid 
and the cytosolic extracts were prepared 24 h after the drug exposure. (B) 
Bax, Bcl-2 and CPP32 cleavage levels. Total cellular extracts were 
obtained 24 h after cell treatment. Tubulin is shown as a control for protein 
loading. Lane 1: control; lane 2: ascorbic acid. 
Fig. 11 – ROS induction by ascorbic acid. Cells were exposed for 2 h to 
0.06 mM and 0.03 mM ascorbic acid for c21/GGT and c21/basal cells, 
respectively. After 24 h, ROS levels were detected by DCFH-DA assay 
and determined by FACS analysis. 
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B1.10: Constitutive catalase activity in c21/GGT cells 
In order to elucidate the cellular basis for lower presence of ROS after H2O2 and AA treatment in 
c21/GGT cells, two major cellular enzymes involved in hydrogen peroxide catabolism, catalase and 
glutathione peroxidase, were investigated. Basal catalase activity was actually two times higher in 
c21/GGT than in c21/basal cells (Fig. 13). This difference reflected the expression of the enzyme as 
documented by Western blot analysis. Treatment with H2O2 induced a further increase of catalase 
activity, more evident in c21/basal cells. A marked induction of catalase activity (56%) was caused by 
AA treatment only in c21/basal cells. In all conditions studied, catalase activity was anyway higher in 
c21/GGT cells. In both clones, no substantial modifications were found in catalase expression after 
treatments. With regard to glutathione peroxidase basal activity, no differences were found between 
the two clones (8.5 ± 1.1 and 8.4 ± 0.8 mU/mg of protein for c21/GGT and c21/basal cells, 
respectively). 
 
 
 
 
 
Fig. 12 – Induction of DNA damage response in c21/GGT and 
c21/basal cells exposed to equitoxic ascorbic acid 
concentration for 2 h. Protein expression of phospho-p53 
(Ser15), RPA, γ-H2AX, and actin (loading control) after 
ascorbic acid treatment. 1 = Control, 2 = ascorbic acid 
treatment (0.06 mM and 0.03 mM for c21/GGT and c21/basal 
respectively). 
Fig. 13 – Catalase activity and expression. Cells were exposed for 2 h to 
H2O2 or to ascorbic acid, and catalase activity and expression were 
determined 24 h after treatment (see Materials and Methods for details). 
Actin is shown as loading control. One representative analysis out of 
three is shown. 1, control; 2, H2O2 (4.6 mM and 100 µM for c21/GGT 
and c21/basal cells, respectively); 3, Ascorbic Acid (0.06 mM and 0.03 
mM for c21/GGT and c21/basal cells, respectively). 
 Chapter B2: γ-Glutamyltransferase-dependent resistance to arsenic trioxide in melanoma 
cells and cellular sensitization by ascorbic acid 
 
 
B2.1: Sensitivity of melanoma cells to arsenic trioxide and ascorbic acid 
The c21/basal cells exhibited an increased sensitivity to arsenic trioxide (IC50, 0.57 µM) as compared 
to the GGT overexpressing c21/ GGT clone (IC50, 2.6 µM) (Fig 1). This finding was consistent with 
our previous observation that the c21/GGT clone is more resistant to oxidative stress-inducing agents 
(e.g., H2O2) [27]. The differential sensitivity to arsenic trioxide paralleled the extent of ROS 
produced by the drug. As observed following treatment with H2O2 or ascorbic acid [27], the 
induction of oxidative stress by arsenic trioxide was more marked in the c21/basal cells (ROS level 
29%) than in c21/GGT cells (ROS level 11%) (Fig. 2). 
Subtoxic concentrations of ascorbic acid (in the range of 0.015-0.030 mM, causing about 10% cell 
growth inhibition) sensitized c21/GGT cells to arsenic trioxide, because the combination resulted in a 
substantially increased growth inhibition (Fig. 1B). In contrast, in the c21/basal cells, which were 
more sensitive to both agents, the combination resulted in an additive inhibitory effect (Fig. 1A). In 
the following experiments, the comparison of drug effects was performed using equitoxic 
concentrations of each agent, i.e. concentrations producing comparable antiproliferative effects in the 
two clones determined 72 h following exposure. Equitoxic concentrations of arsenic trioxide (IC70) 
used in the following experiments were 1 µM and 5 µM for c21/basal and c21/GGT, respectively. 
Ascorbic acid was used at a less toxic concentration (around IC40), i.e., 0.03 mM and 0.06 mM in 
c21/basal and c21/GGT, respectively. Early events associated with drug effects (cell cycle 
perturbation and biochemical modulation) were examined within 24 h of drug exposure to avoid any 
influence of indirect effects of cellular response. 
 
 
 
Fig. 1. Antiproliferative effect of arsenic trioxide alone or in combination with 
ascorbic acid on c21/basal (A) and c21/GGT (B) clones. Cells were treated for 2 h 
with arsenic trioxide alone (10, 5, 1 and 0.1 µM) or in combination with subtoxic 
concentrations of ascorbic acid (0.015 mM and 0.03 mM); cell growth inhibition 
was determined by cell counting 72 h after drug treatment. The results represent the 
mean±SD of three independent experiments. Arsenic trioxide (■); arsenic trioxide + 
ascorbic acid 0.015 mM (
 
); arsenic trioxide + ascorbic acid 0.03 mM (●); ascorbic 
acid 0.015 mM (

); ascorbic acid 0.03 mM (○). 
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B2.2: Induction of oxidative stress and modulation of catalase activity 
ROS induction analysis (Fig. 2) shows that ascorbic acid (0.06 mM, i.e. ~ IC40) enhanced the 
oxidative stress induced by arsenic trioxide (5 µM, i.e. ~ IC70) in cells overexpressing GGT 
(c21/GGTcells), where at this concentration ascorbic acid alone was ineffective in inducing oxidative 
stress. In c21/basal cells exposed to the combination of the two agents at equitoxic concentrations 
(0.03 mM ascorbic acid and 1 µM arsenic trioxide), only an additive enhancement was observed. 
To investigate the response of the two clones to oxidative stress, the levels of catalase, which is a key 
player in antioxidant defenses, were assessed 6 h (Fig. 3A) and 24 h (Fig. 3B) after drug treatments. 
At both time points the basal catalase activity in c21/GGT cells was double than that of c21/basal 
cells. In GGT overexpressing cells, the catalase activity and ROS levels (5%, Fig. 2) were not 
changed by ascorbic acid treatment and only a slight reduction of enzyme activity was evident after 
arsenic trioxide treatment (ROS level 11%, Fig 2). Combined treatment resulted in a substantial 
reduction of catalase activity with an increased ROS level (22%, Fig. 2), both at 6 and 24 h after 
treatment. A different response was found in c21/basal cells, with an early marked increase in the 
Fig. 2. ROS induction by ascorbic acid and arsenic trioxide, alone or in 
combination. Cells were exposed to arsenic trioxide (5 µM and 1 µM for 
c21/GGT and c21/basal cells, respectively) and ascorbic acid (0.06 mM and 
0.03 mM for c21/GGT and c21/basal cells, respectively), alone or in 
combination for 2 h. After 24-h incubation in drug-free medium, cells were 
exposed to 10 µM DCFH-DA for 10 min as specified in Materials and 
Methods. The DCF fluorescence was detected by FACScan flow 
cytofluorimeter. (A) One representative experiment out of three is reported. 
The percentages of DCF-positive cells are reported in each dot plot. (B) The 
histogramshows quantifications of all the experiments performed and the 
results are expressed as mean±SD. Data were analyzed by t test (control vs. 
treatment): 0.005≤p≤0.001 (*), p≤0.001 (**). 
 enzyme activity after single-drug treatment. The combined treatment did not produce changes in 
enzyme activity. The drug-induced changes of catalase activity did not closely reflect enzyme 
expression (Figs. 3C and 3D). 
 
 
 
 
 
 
B2.3: Potentiation of arsenic trioxide-induced apoptosis by ascorbic acid in GGT overexpressing 
cells 
In c21/GGT cells no apoptosis induction was found 72 h after a 2 h treatment with 0.06 mM ascorbic 
acid (Fig. 4). The extent of TUNEL positive cells was appreciably increased with the combination of 
ascorbic acid and arsenic trioxide, as compared to the effect of single agent treatment. In the c21/basal 
cells, which were more susceptible to apoptosis after single-agent treatment, the combined treatment 
resulted in an additive induction of apoptosis, without evidence of sensitization. 
 
 
 
 
 
Fig. 3. Catalase activity. Catalase activity was determined spectrophotometrically 6 h (A) or 24 h (B) after-2 h exposure to arsenic trioxide and 
ascorbic acid, alone or in combination. The histograms show the results of three independent experiments. Enzyme activity for each sample is 
normalized and indicated as mU/mg of total protein content. C) control, AA) ascorbic acid (0.06 mM and 0.03 mM for c21/GGT and c21/basal cells, 
respectively), AT) arsenic trioxide (5 µM and 1 µM for c21/GGT and c21/basal cells, respectively), AA + AT) ascorbic acid and arsenic trioxide. 
The t test was used to compare control data of c21/basal vs. c21/GGT: 0.005≤p≤0.001 (*), p≤0.001(**). (C) Western blot analysis of catalase 
expression performed 24 h after the 2 h treatment. (D) The histogram shows data from three independentWestern blot analyses of catalase, indicated 
as mean±SD, normalized to actin as loading control. 
 50
 
 
 
In order to gain insight into the cell-death mechanism, we assessed proteins and enzymes involved in 
the apoptotic process 24 h after drug exposure. As shown in Fig. 5, Bcl-2 level was not modified by 
single agent treatments in both cell systems, whereas the combination slightly downregulated the Bcl-
2 protein only in c21/GGT cells. 
 
 
 
 
 
 
 Fig. 5. Drug effect on apoptosis-related factors.Western blots were performed 
with total cellular extracts obtained 24 h after cell treatments using the same 
concentrations as in Fig. 3. 
(A) Tubulin was used as a control for protein loading. Lane 1: control; lane 2: 
arsenic trioxide; lane 3: ascorbic acid; lane 4: ascorbic acid and arsenic 
trioxide. (B) Histograms show the quantification of Western blot analyses 
obtained with the Image Quant 5.2 software. Results (mean±SD) are reported 
as relative expression normalized to the tubulin used as loading control. T test 
were performed (control vs. treatment) and p values are indicated as follows: 
(*) 0.001≤p≤0.0005, (**) p≤0.0005, (***) p≤0.00001. 
Fig. 4. Apoptosis induced by arsenic trioxide and ascorbic acid, alone or in combination. Cells were exposed for 2 h to the same concentrations 
of ascorbic acid and arsenic trioxide, alone or in combination, as in Fig. 3. Apoptosis was detected by TUNEL assay 72 h after the end of 
treatment and determined by FACS analysis. (A) The numbers in the dot plots indicate the percentage of TUNEL-positive cells. (B) 
Quantification of three independent assays; each result is expressed as mean±SD. Data were analyzed by t test (control vs. treatment): 
0.005≤p≤0.001 (*), p≤0.001 (**). 
  
 
Sensitization to apoptosis by the drug combination in c21/GGT cells was also supported by CPP-32 
cleavage. Indeed, whereas single-agent treatments caused only a marginal cleavage, the combination 
resulted in an evident effect. Sensitization was less evident in the more sensitive c21/basal cells. Cyt 
C release in c21/GGTcells was far more evident after the combined treatment than after the single-
agent treatment. Again, the effect of the combination was less marked in the c21/basal cells. 
Since macroautophagy is an accepted mechanism of cellular recovery which may confer resistance to 
cellular injuries, such as oxidative stress, the LC-3 I/II level was determined as a reliable marker of 
autophagosome formation. The active form LC-3 II was evident in both clones after single-agent 
treatment, but it was not detectable after combined treatment. 
B2.4: Response to DNA damage 
Cell cycle analysis performed 24 h after a 2-h treatment with the same equitoxic concentrations of 
ascorbic acid and arsenic trioxide as in previous assessments, indicated cell accumulation in S phase 
after each treatment, both in c21/GGT and c21/basal cells (Fig. 9). As shown in Fig. 6, BrdU 
incorporation analysis indicated that cells accumulated in S phase after drug treatments were not 
synthesizing DNA, thus supporting the activation of an efficient DNA damage checkpoint in both cell 
systems. 
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Western blot analysis of the proteins involved in DNA damage response documented the 
phosphorylation of histone γ−H2AX and p53 (Fig. 7). However, in c21/basal cells these modulations 
already occurred with single-agent treatment, which was in keeping with cell sensitivity. In contrast, 
the activation of these DNA damage markers in c21/GGT cells was evident only after combination 
treatment. A lack of activation of RPA-2 was consistent with the type of DNA lesions induced by the 
oxidative stress (i.e., single-strand breaks). 
 
 
 
B2.5: Different modulation of ASK-1 pathway in the two melanoma cell clones 
Since the stress-activated protein kinase p38 is known to be involved in the regulation of catalase 
expression following oxidative stress [28], we examined the phosphorylation status of p38 and ASK1, 
which is an upstream regulator of this stress-activated pathway (Fig. 8). The c21/basal clone showed 
an evident phosphorylation of ASK-1 both under single-agent and combined treatment, whereas for 
the c21/GGT clone the activated (phosphorylated) form was increased only following combination 
treatment. Phosphorylation of p38 was higher in the c21/GGT clone than that in the c21/basal clone, 
Fig. 6. Bromodeoxyuridine (BrdU)  incorporation analysis in c21/GGT and c21/basal cells. 
Cells were exposed for 2 h to arsenic trioxide (5 µM and 1 µM for c21/GGT and c21/basal 
cells, respectively) and ascorbic acid (0.06 mM and 0.03 mM for c21/GGT and c21/basal 
cells, respectively), alone or in combination. Twenty-four h after 2 h drug treatment cells 
were exposed to BrdU for 1 h and then processed for analysis, as described in Material and 
Methods. One representative experiment of three is shown. 
Fig. 7. Induction of DNA damage response in c21/GGT and c21/basal cells exposed 
to ascorbic acid and arsenic trioxide, alone or in combination. Twenty-four h after 2 h 
drug treatment, cells were lysed and processed for Western blotting. (A) Lane 1: 
control; lane 2: ascorbic acid treatment (0.06 mM for c21/GGT and 0.03 mM for 
c21/basal clone); lane 3: arsenic trioxide (5 µM for c21/GGT and 1 µM for c21/basal 
clone); lane 4: ascorbic acid and arsenic trioxide. Actin was used as loading control. 
(B) Histograms show the quantification of Western blot analyses using the 
ImageQuant 5.2 software. Data (mean±SD) are reported as relative expression 
normalized to the actin used as loading control. Data were analyzed by t test (control 
vs. treatment): 0.005≤p≤0.001 (*), p≤0.001 (**). 
 both in basal control conditions and after single-agent treatment whereas combined treatment resulted 
in a lack of p38 activation in both melanoma clones. Modulation of p21 levels appeared to parallel the 
pASK-1 one. 
 
 
 
 
 
 
 
 
 
Fig. 8. Modulation of ASK1 pathway in two melanoma clones. (A) 
P21, p38 together with pp38 and pASK1 protein levels were 
analyzed by Western blotting 24 h after drug treatment. Actin and 
tubulin were used as loading controls. One representative 
experiment of three is shown. (B) Histograms show the 
quantification of Western blot analyses using the ImageQuant 5.2 
software. Results (mean±SD) are reported as relative expression of 
each protein normalized to the loading control (actin or tubulin). 
Fig. 9. Cell cycle distribution analysis. Twenty-four h after a 2 h exposure to ascorbic acid and arsenic 
trioxide, alone or in combination, cell cycle distribution was determined by flow cytometry and data 
were analyzed with the Cell Quest® software. 
The histogram shows the distribution of cells in G1 (white column), S (grey column) or G2/M (black 
column) phase. The results are expressed as mean ± SD from three independent experiments. 
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Chapter B3: Membrane gamma-glutamyl transferase activity promotes iron-dependent 
oxidative DNA damage in melanoma cells 
 
B3.1: Basal levels of DNA damage and oxidized bases 
Two distinct human melanoma cell clones were used: the c21/basal clone, exhibiting low GGT 
activity (~0.3mU/mg protein), and the c21/GGT clone, presenting with high enzyme activity 
(~90mU/mg protein). To evaluate the potential role of GGT in inducing DNA damage, basal levels of 
DNA damage were analyzed in both melanoma clones by alkaline comet assay. Under normal culture 
conditions, c21/GGT cells showed higher levels of basal DNA damage as compared to c21/basal 
cells, and this difference was accompanied by higher levels of oxidized bases, as detected by Fpg 
treatment (Fig. 1A and B).Interestingly, when cells were treated with the GGT-specific inhibitor 
ABBA, the difference in basal DNA damage between the two clones was suppressed (Fig. 1C). 
 
 
 
 
 
 
 
Fig.1. Basal levels of DNA damage and oxidized bases in c21/basal and c21/GGT cells. 
Cells were collected after 24 h from seeding and processed for the comet assay. Where 
indicated cells were incubated with GGT competitive inhibitor ABBA. 
Data in Fig. 1B were obtained by subtracting the level of DNA damage observed for no 
treated samples from Fpg treated ones. Each value represents the mean±S.D. from three 
independent experiments. Data were analyzed by one-way ANOVA with Newman–Keuls 
multiple comparisons test. (A) (*) p < 0.001, (**) p < 0.05 compared with “c21/basal”; (***) 
p < 0.001 compared with “c21/GGT”; (B) (§) p < 0.05; (C) (*)p < 0.001 compared with 
“c21/GGT”; (n.s.) not statistically different from“c21/basal”. 
 B3.2: Cell proliferation and apoptosis 
The possibility that the differences observed might depend on different proliferation or apoptotic rates 
between the two clones was investigated. No differences in cell cycle distributions between the two 
clones were observed by flow cytometry, neither in basal conditions nor after a 24 h treatment with 
GGT-inhibitor ABBA (Fig. 2A). Moreover, when apoptosis was analyzed by TUNEL assay, in basal 
conditions both clones presented with very low, negligible percentages of apoptotic cells and 
inhibition of GGT by ABBA did not produce any effect (Fig. 2B). 
 
 
 
B3.3: GGT expression and oxidative metabolism 
A correlation has been reported to occur between DNA oxidative damage and cell metabolic rate [29]. 
Previous studies in our laboratories showed that the in vivo growth rate of tumors obtained from 
c21/GGT cells (after transplantation in immunodeficient mice) was higher than tumors derived from 
c21/basal cells [5]. Interestingly, c21/GGT cells presented with a higher glucose uptake than c21/basal 
(Fig. 3A)—an observation in agreement with their significantly higher proliferation rate in vitro (data 
not shown). Higher glucose uptake in c21/GGT cells was partially prevented by a 24 h pre-treatment 
with GGT-inhibitor ABBA (Fig. 3B).     
 
 
 
 
Fig. 2. Cell cycle distribution and apoptotic rate in basal and ABBA 
treated melanoma clones. Cells were incubated for 24 h in the 
presence/absence of GGT competitive inhibitor ABBA. (A) Cell 
cycle distribution was determined by flow cytometry. The 
percentages of cells in G1, S or G2 phases are reported in each 
histogram. (B) Apoptosis was detected by TUNEL assay. Numbers 
in the dot-plots indicate the percentage of tunel positive cells. One 
representative experiment out of three was reported. 
Fig. 3. Deoxy-glucose transport in melanoma clones. 
(A) Time course of glucose uptake in melanoma 
clones; (B) effect of a 24 h ABBA pre-incubation on 
c21/GGT glucose uptake. Data are expressed as 
glucose uptake in the absence of cytochalasin Bminus 
uptake in the presence of cytochalasin B. Each value 
represents the mean±S.D. from five independent 
experiments. Data were analyzed by two-way 
ANOVA (A) or Student’s t test (B). (*) p < 0.0001; 
(**) p < 0.001. 
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B3.4: Stimulation of GGT activity and DNA damage 
The possibility that the differences observed in basal DNA damage could be related to the pro-oxidant 
activity of GGT was investigated in more detail. As can be seen in Fig. 4A and B, when the c21/GGT 
clone was incubated in the presence of substrate GSH, transpeptidation acceptor glycyl-glycine 
(“GGT stimulation”), and ADP-chelated iron, a marked increase in DNA damage levels was observed 
(Fig. 4A) along with a marked acceleration of GSH consumption (Fig. 4B). In the absence of glycyl-
glycine such effects were markedly lower. Conversely, when GGT activity was stimulated in 
c21/basal cells, no differences in GSH hydrolysis or DNA damage –despite the presence of ADP-
chelated iron – were observed (Fig. 4C and D). On the other hand, when purified GGT was 
exogenously added to incubation mixture, GSH consumption and increased DNA damage were 
concomitantly observed (Fig. 4C and D). 
 
 
In agreement with what was observed in the case of basal DNA damage levels, significantly higher 
levels of oxidized bases (oxidized purines) were detected by Fpg treatment in GGT-stimulated 
c21/GGT cells (Fig. 5A and B). 
 
Fig. 4. Effects of GGT stimulation on DNA damage and 
GSH hydrolysis in melanoma clones. (A and B) c21/GGT 
cells were incubated in RPMI medium containing GSH, 
ADP-chelated FeCl3 in the presence (“GGT-stimulated”) or 
absence (“control”) of transpeptidation acceptor glycyl-
glycine. Each value represents the mean±S.D. from five 
independent experiments. Data were analyzed by Student’s t 
test; (*) p < 0.0001. (C and D) c21/basal cells were 
incubated in RPMI medium containing GSH, ADP-chelated 
FeCl3 in the presence or absence of transpeptidation acceptor 
glycyl-glycine and purified GGT. a) Control; b) control with 
glycyl-glycine added; c) control with purified GGT added; d) 
control with glycyl-glycine and GGT added. Each value 
represents the mean±S.D. from three independent 
experiments. Data were analyzed by one-way ANOVA with 
Newman–Keuls multiple comparisons test. (*) p < 0.05 
compared with “a”; (**) p < 0.001 compared with “b”; (***) 
p < 0.001 compared with “a”; (n.s.) not statistically different 
from “a”. 
  
The relationships between GSH hydrolysis and DNA damage were further investigated by plotting 
GSH consumption data against DNA damage levels. Data were analyzed in order to isolate the effects 
truly depending on the sole GGT activity, i.e. by subtracting control GSH hydrolysis from GSH 
hydrolyzed in conditions of GGT stimulation. Fig. 6 shows the graph obtained by plotting “net” GSH 
hydrolysis values in c21/GGT cells vs. “net” DNA damage levels. 
 
As can be seen, a strong correlation between the two parameters was found (R2 = 0.867), further 
confirming the role of enzyme activity in iron-dependent DNA damage. Such a role was also 
supported by data independently obtained with two GGT inhibitors, ABBA and serine–boric acid 
complex (SBC). As shown in Fig. 7, both ABBA and SBC concomitantly inhibited GSH hydrolysis 
and DNA damage in GGT-stimulated c21/GGT cells. 
 
 
 
 
 
 
Fig. 5. Effect of GGT stimulation on bases oxidation in c21/GGT cells. c21/GGT cells 
were incubated in RPMI medium containing GSH, ADP-chelated FeCl3 in the presence 
(“GGT-stimulated”) or absence (“control”) of transpeptidation acceptor glycyl-glycine. 
Data in Fig. 4B were obtained by subtracting the level of DNA damage observed for no 
treated samples from Fpg treated ones. Each value represents the mean±S.D. from three 
independent experiments. Data were analyzed by oneway ANOVA with Newman–Keuls 
multiple comparisons test. (*) p < 0.001 compared with “control”; (**) p < 0.001 
compared with “GGT-stimulated” and “control Fpg”; (§) p < 0.01. 
Fig. 6. Direct relationship between GSH hydrolysis and DNA damage in 
c21/GGT clone. Data were obtained from different experiments 
performed on c21/GGT clone by subtracting GSH hydrolyzed and 
percentage of tail DNA values in “GGTstimulated” samples from 
“control” ones. R2 = 0.867. 
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B3.5: Mechanisms of GGT-mediated DNA damage 
The mechanism by which GGT promotes DNA damage was further investigated in experiments 
performed in the presence of iron chelator DFO. As shown in Fig. 8, DFO completely prevented DNA 
damage, both in GGT-stimulated cells and in controls incubated in the absence of transpeptidation 
acceptor glycyl-glycine (Fig. 8A), confirming the participation of extracellular iron in the GGT-
dependent damage. GSH consumption was unaffected by DFO, indicating that enzyme activity itself 
was not disturbed by DFO addition (Fig. 8B). 
 
 
 
 
 
 
Fig. 7. Effects of GGT inhibitors ABBA (A and B) and SBC (C and D) 
on GGT-induced DNA damage and GSH hydrolysis in c21/GGT clone. 
c21/GGT cells were incubated in RPMI medium containing GSH, ADP-
chelated FeCl3 in the presence (“GGT-stimulated”) or absence 
(“control”) of transpeptidation acceptor glycyl-glycine. Where indicated 
GGT competitive inhibitors ABBA or SBC were added to incubation 
mixtures. Each value represents the mean±S.D. from three independent 
experiments. Data were analyzed by one-way ANOVA with Newman–
Keuls multiple comparisons test. (*) p < 0.001 compared with “control”; 
(**) p < 0.001 compared with “GGT-stimulated”; (n.s.) not statistically 
different from “control”. 
Fig. 8. Effects of iron-chelator DFO on GGT-induced DNA damage (A) and GSH hydrolysis (B) in c21/GGT clone. c21/GGT cellswere 
incubated in RPMImedium containing GSH, ADP-chelated FeCl3 in the presence (“GGT-stimulated”) or absence (“control”) of 
transpeptidation acceptor glycyl-glycine. Where indicated the iron chelator DFO was added to incubation mixtures. Each value represents 
the mean±S.D. from three independent experiments. Data were analyzed by one-way ANOVA with Newman–Keuls multiple comparisons 
test. (*) p < 0.001, (**) p < 0.01 compared with “control”; (***) p < 0.001 compared with “GGT-stimulated”; (n.s.) not statistically 
different from “GGT-stimulated”. 
 A marked decrease in DNA damage was also observed when cells were incubated in the presence of 
superoxide dismutase (SOD) and catalase (CAT), while GGT-mediated GSH hydrolysis remained 
unaffected (Fig. 9A and B). The same effects were observed when using the chain breaking 
antioxidants α-tocopherol (Fig. 9C and D), BHT or Trolox C (Fig. 9E and F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Effects of antioxidants on GGT-induced DNA damage. c21/GGT cells were 
incubated in RPMI medium containing GSH, ADP-chelated FeCl3 in the presence 
(“GGTstimulated”) or absence (“control”) of transpeptidation acceptor glycyl-
glycine.Where indicated superoxide dismutase (SOD) and catalase (CAT),α-
tocopherol (VitE), butylated hydroxytoluene (BHT) or Trolox C were added to 
incubation mixtures. Eachvalue represents the mean±S.D. fromthree independent 
experiments. (*) p < 0.001, (**) p < 0.05compared with “control”; (***) p < 0.001 
compared with “GGT-stimulated”; (n.s.) not statistically different from “GGT-
stimulated”; (n.s.1
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Conclusion 
Section A: Hsp90 
 
In conclusion, the available evidence based on the biochemical, pharmacodynamic and cellular effects 
indicated that the class of natural compounds we tested may represent a novel series of Hsp90 
inhibitors. It is evident that a major limitation of these compounds is the low potency in target 
inhibition, which requires micromolar concentrations to inhibit cell proliferation. Also considering the 
chemical features of these agents, we cannot rule out the possibility of interactions with other cellular 
components. If this is the case, these interactions may have a detrimental effect by limiting an 
effective inhibition of the primary target. However, our approaches aimed at modifying the basic 
structure of these agents provide evidence that specific variations may improve the Hsp90 inhibitory 
effect. In particular, compounds 16 and 17, containing a lipophilic chain linked to the azaphilone 
tricyclic ring system, brought about substantially increased binding to the enzyme, accompanied by 
relevant cytotoxic effects. Finally, we have documented the pharmacological interest of a 
representative compound of the novel series. Current efforts are directed toward optimization of the in 
vivo properties of selected analogues. 
Curcumin has been shown to have multiple biological activities. The chemopreventive and anti-tumor 
effects of curcumin have been related to its ability to interfere with several signal transduction 
pathways which are involved in cell proliferation and/or apoptosis [30]. However, the underlying 
molecular mechanisms of these cellular effects are not well defined. In our study, we have provided 
evidence that curcumin at cytotoxic/anti-proliferative concentrations was able to directly inhibit 
Hsp90 function, thereby promoting the chaperone dissociation and the degradation of several Hsp90 
client proteins. This finding may account for curcumin’s ability to interfere with multiple signal 
transduction pathways, because Hsp90 plays a critical role in stabilization of several proteins 
implicated in the control of cell growth and malignant transformation [31, 32]. As compared with the 
geldanamycin derivative, 17-AAG, a well-established Hsp90 inhibitor, the potency of curcumin was 
substantially lower, because the inhibitory effects could be detected in the micromolar range of 
concentrations. This was consistent with lower antiproliferative potency and a weaker Hsp90 binding. 
The mechanism of curcumin-Hsp90 interaction remains to be defined. A lack of up-regulation of 
Hsp70 suggests a mechanism of interaction different from that of geldanamycin. 
 However, in preliminary limited proteolysis experiments, the proteolysis pattern observed on HSP90a 
indicated a protection of the N-terminal domain from the enzymatic hydrolysis. 
Based on the observations that Hsp90 hyperacetylation by HDAC inhibitors disrupts its chaperone 
function [33-34], we have investigated the efficacy of curcumin in combination with wellknown pan-
HDAC inhibitors. Our results provide evidence that the potentiation of the anti-proliferative/cytotoxic 
activity of both vorinostat and panobinostat by subtoxic concentrations of curcumin (~IC20) might be 
mediated by inhibition of Hsp90 function. Indeed, the combinations of curcumin and HDAC 
inhibitors, at concentrations which produced negligible effects when used alone, resulted in a marked 
induction of apoptosis. The cellular death could be related to a synergistic inhibition of Hsp90 
activity, as under the same conditions, the combined treatment caused an almost complete depletion 
of several client proteins following 24 h exposure. The synergistic interaction of curcumin and HDAC 
inhibitor at target level was supported by co-immunoprecipitation experiment indicating an early (4 h) 
shift of the association of the Raf-1 from Hsp90 to Hsp70. Previous reports have shown that the shift 
in the chaperone association of the client proteins to the Hsp70-containing unstable multichaperone 
complex induces polyubiquitylation and degradation of the client proteins by the 26 S proteasome [35, 
36, and 37]. 
The most striking finding of this study was the longlasting effect of the combination, which persisted 
even following removal of the drugs. As a consequence of the persistent inhibition, the enhancement 
of apoptosis did not required prolonged exposure. Thus, given the relatively rapid reversibility of 
cellular effects of HDAC inhibitors [38] and curcumin, these combinations may have therapeutic 
implications. Since Hsp90 acetylation may induce a modified conformation of the enzyme, a tentative 
explanation of the synergistic interaction between HDAC inhibitor and curcumin may be that, as a 
consequence of allosteric effects, changed conformation of the acetylated protein favors the 
curcumin–Hsp90 interaction. A synergistic interaction between HDAC inhibitors and standard 
inhibitors of Hsp90 (i.e. geldanamycin analogues) has already been reported in leukemia or sarcoma 
cells [39-40], and the sensitization has been ascribed to the modulation of Hsp90 chaperone function 
by its acetylation status [41]. 
In conclusion, our findings reveal a novel mechanism of action of curcumin, which is consistent with 
modulation of signaling pathways. The effects of curcumin described in this manuscript support 
previous observations indicating the ability of curcumin to down-regulate p210bcr/abl, a client protein 
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of Hsp90 [42]. Our obsvervations may be relevant to the therapeutic applications of both HDAC 
inhibitors and curcumin. Indeed, the therapeutic efficacy of these agents as single-agent therapy is still 
limited for pharmacological and pharmaco-dynamic reasons. Indeed, besides problems related to 
bioavailability and metabolism [43], the expected reversibility of target inhibition represents a major 
drawback of these target-specific agents. 
Relevant to this point is the observation that the sensitization for drug-induced apoptosis could be 
produced by very low drug concentrations which are achievable in vivo and expected to be well 
tolerated. Both curcumin and HDAC inhibitors have been reported to enhance citotoxicity of various 
antitumor agents [44, 45-46]. The present study supports the potential interest of a novel combination 
which can be translated into the design of novel therapeutic approaches. 
 
Conclusion 
Section B: GGT 
 
In the melanoma cell system used in our study, we found that overexpression of GGT was associated 
with a reduced sensitivity to oxidative stress caused by H2O2, as well as to cytotoxic effects of 
ascorbic acid. The GGT-overexpressing c21/GGT cells were markedly more resistant to H2O2 and 
AA treatments, approx. 50- and 2-fold more than the c21/basal clone. The ability of ascorbic acid to 
induce indirectly oxidant effects is a well established phenomenon, described in different cell types 
and different culture conditions, and likely related to AA interactions with trace levels of transition 
metal ions present in many incubation media. Thus, an increased resistance of c21/GGT clone to 
oxidative injury could explain both observations. Only moderate levels of ROS were indeed produced 
in c21/GGT cells following exposure to relatively high concentrations of H2O2, while paradoxically 
higher levels of ROS were produced in c21/basal clone exposed to substantially lower (equitoxic) 
H2O2 concentrations. Consistent with this finding, H2O2 treatment produced no DNA damage 
response in c21/GGT clone, i.e. neither histone γ–H2AX phosphorylation nor S phase checkpoint 
activation, wherease a typical DNA damage response was found in c21/basal clone, with S phase cell 
accumulation and phosphorylation of both histone γ–H2AX and p53. The increased catalase 
expression and activity observed in untreated c21/GGT cells (two times higher as compared to 
c21/basal) could account for the increased ability of this clone to tolerate oxidative stress, and likely 
reflects an adaptation phenomenon. In fact, GGT-mediated metabolism of extracellular GSH is known 
 to produce prooxidant effects, including production of H2O2.The occurrence of low but persistent 
oxidative stress in c21/GGT cells is consistent with a higher GSSG/GSH ratio. It is likely that the 
ongoing GGT-mediated production of prooxidants can induce activation of protective pathways, 
including catalase expression. 
Anyway, a short-time exposure to cytotoxic concentrations of hydrogen peroxide or AA resulted in a 
significant induction of catalase activity, but not of its expression level. Thus it is conceivable that an 
acute oxidative stress causes an activation of the catalase already present in the cell, whereas a low 
persistent oxidative stress, present in the GGT-overexpressing cells as a consequence of GGT-
mediated extracellular metabolism of GSH, results in modulation of protein expression. 
Ascorbic acid was used in this study as a prooxidant agent to explore possible pharmacological 
implications of the features acquired by the GGT-overexpressing phenotype, because AA may have a 
therapeutic potential in melanoma. In spite of a comparable perturbation induced by AA on cell cycle 
with partial accumulation of cells in S-phase, the final outcome was substantially different in the two 
clones. In the more sensitive c21/basal clone, typical manifestations of oxidative stress were observed, 
including production of ROS, DNA damage response (γ–H2AX and p53 phosphorylation) and 
activation of cell death pathways (cytochrome C release and caspase activation). In contrast, 
following AA treatment the less responsive c21/GGT clone exhibited only marginal signs of 
genotoxic stress, with no evidence of apoptotic cell death. Such findings might be explained by the 
occurrence in c21/GGT clone of marginal, easily repairable DNA damage, and/or by a lack of 
recognition of DNA lesions. AA is known to induce prooxidant effects, and it was shown that the 
formation of H2O2 is a critical step in its cytotoxicity. In agreement with this interpretation, the 
addition of exogenous catalase provided a substantial protection in our experiments. Therefore, the 
increased resistance of c21/GGT cells to AA more likely reflects their increased ability to detoxify 
H2O2 following upregulation of cellular catalase activity. 
It is well established that prooxidant rather than antioxidant effects of AA depend on its interactions 
with transition metal ions, in particular iron. Iron can also interact with H2O2 in the so-called Fenton 
reaction, leading to production of highly reactive and toxic hydroxyl radicals. Indeed, data reported 
indicate that free, redox-active iron is implicated in the phenomena observed. When the iron-chelating 
agent DFO was added to incubation mixtures, attenuation of citotoxicity of both H2O2 and AA was in 
fact observed, and even stronger protection was achieved using 2,2’-bipyridyl, an agent able to 
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permeate cells and hence to chelate both extracellular and intracellular free iron. Relevant to this point 
is the observation that, following exposure to an equimolar concentration (60 µM), the differential 
toxicity of AA between the two clones can be abolished by treating the c21/basal clone with 2, 2’-
bipyridyl. The lower sensitivity of the GGT-expressing clone could thus support a lower content of 
intracellular free iron, required for the efficiency of redox-cycling processes, necessary to overdraw 
the inner oxidative burst. Indeed, free iron is known to participate in reaction resulting in free radical 
formation and oxidative stress leading to DNA damage and cell death. On the other hand, we have 
previously shown that iron-mediated oxidation of extracellular AA can favour its uptake by melanoma 
cells, and that this process is suppressed by iron chelation. Protection offered by DFO and bipyridyl 
against AA effects may also depend on this phenomenon. 
In conclusion, our study provides evidence that overexpression of GGT in melanoma cells is 
associated with increased resistance to oxidative stress depending on the induction of protective 
mechanisms against reactive oxygen species. Such a resistance to oxidative stress can explain the 
decreased susceptibility of GGT-expressing cells to effects of ascorbic acid. The marked resistance of 
GGT-overexpressing cells to oxidative stress can thus have important pharmacological implications 
because production of oxidative stress is a relevant event in the apoptotic response to several 
cytotoxic agents. Figure beneath depicts our proposed mechanism of cellular stress induced by H2O2 
or AA, and the possible defence mechanisms involved.  
 
Catalase is responsible for degradation of endogeneous and exogenous H2O2. Previous studies 
showed an enhancement of catalase activity by repeated low-dose H2O2 exposure [47] and the 
increase enzyme activity was implicated as a resistance factor in response to oxidative stress-inducing 
agents and cisplatin [48]. 
 Our results showed that single-agent treatment (ascorbic acid or arsenic trioxide) caused only a weak 
ROS induction in c21/GGT cells. Since the basal levels of catalase were unaffected by these drugs, it 
is conceivable that in these cells the basal catalase activity is an efficient protective system to fight 
oxidative stress triggered by these agents. On the other hand, since induction of enzyme activity in 
c21/basal cells was found after single-agent treatment, it is likely that these cells were more sensitive 
to drug-induced oxidative stress because little catalase activity was promptly available. This 
interpretation is consistent with the higher level of ROS found in c21/basal cells. 
The combination of two stress-inducing agents, ascorbic acid and arsenic trioxide, resulted in a 
marked antiproliferative effect in c21/GGT cells, similar to that produced in the c21/basal cells. In 
spite of a differential effect of the single agents on the catalase activity of the two clones, the enzyme 
activity was similar after the combined treatment. Under these conditions, which resulted in a 
limitation of catalase activity, higher levels of ROS were detected. These results suggest that ascorbic 
acid and arsenic trioxide together inhibited catalase activity in the resistant clone and prevented 
enzyme induction in the basal one. 
The lack of phosphorylation of p38 kinase could account for the modulation of catalase at least in the 
c21/GGT clone, because p38 activation has been implicated in catalase mRNA stabilization [47]. 
A comparison of the cellular response (apoptosis, DNA damage and cell cycle perturbation) in the 
two clones supports that the defense mechanisms developed by c21/GGT cells are efficient in 
protecting these cells against cellular injury induced by the single agents. When the same agents were 
used in combination the defense mechanisms of GGT-overexpressing cells were partially overcome, 
resulting in an increased DNA damage response and cell death. Again, the c21/basal clone which was 
already responsive to single-agent treatment, showed an enhanced stimulation of DNA damage 
response to the combination. 
It has been shown that arsenic oxides can cause release of iron from ferritin, resulting in the formation 
of reactive oxygen species [48]. Ascorbic acid can produce the same effect and, when administered in 
combination, can greatly potentiate iron release and oxidative stress induced by arsenic [49]. The 
superoxide anion formed in the process can generate H2O2, either by spontaneous dismutation or by 
reaction with ascorbic acid itself [50]. H2O2 and iron together are well-known promoters of the 
formation of highly cytotoxic hydroxyl radicals through the Fenton reaction [51]. The stronger 
efficacy of the combined ascorbic acid and arsenic trioxide treatment could therefore be ascribed to a 
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stronger and more persistent oxidative stress, resulting from i) the synergic release of iron by arsenic 
trioxide and ascorbic acid from cellular stores, and ii) the promotion by ascorbic acid of iron-mediated 
production of superoxide anion and other cytotoxic oxygen species, leading to a burst of oxidative 
stress capable of impairing the cellular defense mechanisms. An additional explanation may be that 
the redox reactions initiated by ascorbic acid and iron may eventually help maintain arsenic in the 
more toxic As3+ form [52]. 
Mitochondria could play a crucial role in the decision of the cellular fate, such as the switch between 
apoptosis and recovery from oxidative injury including activation of autophagy, an event that depends 
on the cellular background and on the nature and strength of the stimulus. This protective process, 
activated in both clones, but more efficiently in GGT-overexpressing cells as indicated by LC-3 II 
induction, may contribute to cell survival. 
Following the combined treatment, the protective mechanism was not activated, and the lack of 
activation is likely to favor apoptosis. 
Consistent with this interpretation is the observed modulation of the ASK1/p38 pathway, which is 
known to be a cellular oxidative stress sensor that differentially activates intracellular pathways, 
resulting in apoptosis or survival depending on the cell ability to respond to oxidative stress [53]. As 
summarized in the figure below, ASK1, once activated, may phosphorylate a number of MAPKs, 
depending on the extent of cellular oxidative stress. In particular, activation of p38 is related to 
catalase stabilization and enhanced ability to fight ROS, resulting in cell protection; otherwise, if the 
oxidative stress is too strong, other MAPKs are involved, triggering apoptosis through p21 induction 
[53].  
 
 
 
 The stress-resistant clone showed a higher basal activation of p38 than the sensitive one and the 
phosphorylated form was already evident after single-agent treatment, suggesting that the moderate 
stress induced by the single agents can be tolerated at least in part. The activation of proapoptotic 
signals likely requires an overwhelming stress, resulting in ASK-1 activation and p21 induction. Since 
p38 may have a protective function in the stress response, it is conceivable that the lack of kinase 
activation in both clones reflects a cell decision towards cell death rather than recovery. 
In conclusion, our study provides a cellular basis for overcoming the protective mechanisms 
implicated in the resistance of melanoma cells to oxidative stress. Indeed, although GGT-
overexpressing cells were resistant to oxidative stress, cellular sensitization could be achieved by the 
appropriate combination of stress-inducing agents. 
The prooxidant action of ascorbic acid might be exploited to enhance the activity of arsenic trioxide, a 
clinically available drug already proposed for the treatment of advanced metastatic melanoma [54]. 
Since the natural resistance of melanoma to conventional cytotoxic therapy likely reflects the cell 
ability to survive under oxidative stress conditions [55], our study supports the pharmacological 
interest of modulating the response to oxidative damage to improve antitumor efficacy. The ability of 
the subtoxic ascorbic acid concentrations to sensitize oxidative stress-resistant melanoma cells to 
arsenic trioxide may have therapeutic implications, and could be exploited to develop novel treatment 
approaches, based on this well-tolerated combination. 
Early reports described the increase of GGT activity in cells and tissues exposed to carcinogenic 
treatments, a phenomenon often followed later on by increased cell proliferation and neoplastic 
growth. In recent years several studies have described alterations of GGT levels in a number of human 
tumors, and a new perspective has been forwarded proposing GGT as an “active” factor in 
development of a more aggressive and resistant phenotype of cancer cells [4].  
Against this background, our data indicate that GGT overexpression in melanoma cells is per se 
associated with increased background levels of DNA damage and oxidized bases. The effect is 
magnified when ADP-chelated iron is exogenously added, confirming that the mechanism implicated 
includes metal ion redox-cycling reactions. Basing on this finding, genotoxicity could be thus 
included among the effects of the more pro-oxidant environment generated by GGT-overexpressing 
cells. 
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On the other hand, it has been suggested that the genome of cancer cells could be more prone to 
oxidative damage due to the higher rate of metabolism associated with increased cellular proliferation 
[56]. Several studies have documented a relationship between cell proliferative status and induction of 
DNA damage and repair capabilities, and differences of these parameters were observed in cells as 
they proceed along G1, S and G2 phases of the cell cycle [57, 58]. Moreover, some authors have 
proposed that apoptosis associated DNA fragmentation could also be detected by comet assay, and 
identified the apoptosis-type DNA fragmentation in the so-called ‘hedgehog comets’ [59, 60]. It has 
however been observed that ‘hedgehog comets’ are regularly produced by agents – e.g.H2O2– 
inducing DNA lesions that can be readily repaired, and therefore such comets probably do not 
represent a reliable indicator of apoptosis [5]. 
On the basis of the considerations above, we have investigated whether the higher DNA damage 
basally observed in GGT-overexpressing cells could be explained by differences in cell cycle 
distribution or by a higher apoptotic rate. No differences were observed between the two clones with 
respect to cell cycle distribution or apoptotic rate. Moreover, when the GGT-specific inhibitor ABBA 
was added to cell culture media, the difference in basal DNA damage was completely abolished, 
while no effect was produced on cell cycle distribution or apoptotic rate. 
It is known that a source of endogenous ROS within the cell is represented by oxidative metabolism, 
and the question then arises, which can be the predominant mechanism operating in production of the 
observed DNA damage, i.e. whether the effect is promoted i) directly, through a GGT-mediated 
production of DNA-damaging reactive species, or ii) indirectly, through the upregulation by GGT 
activity of cellular processes involved in oxidative metabolism. 
With respect to the “indirect” hypothesis, previous studies have shown that GGT expression may 
represent a growth advantage, insofar as GGT pro-oxidant effects can modulate the redox-sensitive 
transcription factors NF-kB and AP-1, involved in cell proliferation [61]. It is in fact well assessed 
that tumors obtained from c21/GGT cells transplanted in nude mice indeed grow faster than those 
derived from c21/basal cells [62]. A relationship was also documented between exposure to low grade 
oxidative stress and increased expression of GLUT1 glucose transporter, through the activation of 
AP-1 [63]. As shown by our results, a higher basal glucose transport is indeed present in c21/GGT 
cells as compared to c21/basal—an effect that was significantly decreased after 24 h preincubation 
with the specific GGT-inhibitor ABBA. GGT-rich cells appear thus to enjoy higher glucose 
 availability as compared to GGT-poor cells, a phenomenon likely leading to a higher metabolic rate 
and higher oxidative DNA damage. 
On the other hand, potentially damaging reactive species are also directly produced by GGT pro-
oxidant reactions (“direct hypothesis”). 
As mentioned above, these are able not only to modulate redox-sensitive signal transduction, but also 
to produce direct (metal ion-mediated) oxidative damage to biological molecules such as lipids and 
proteins. In agreement with previous data, our results demonstrate that conditions of stimulated GGT 
activity are also accompanied by increased DNA damage, and that such damage is indeed oxidative in 
nature. ABBA or serine–boric acid complex blocked GSH consumption and the corresponding DNA 
damage at the same time. 
Moreover, when purified GGT was exogenously added to c21/basal cells, GSH hydrolysis and 
increased DNA damage were concomitantly observed. Also, a strong correlation was observed 
between net levels of GSH hydrolysis and DNA damage, further confirming a strict relationship 
existing between the two. 
Metal ions redox cycling with production of reactive oxygen species is a critical step in the 
phenomena described. GGTdependent DNA damage was in fact completely inhibited in the presence 
of the extracellular iron chelator DFO, as well as in the presence of superoxide dismutase and 
catalase. 
Previous reports described lipid peroxidation (LPO) among the prooxidant effects produced by GGT 
activity, both in a cellular [64] and cellular systems [65, 66, and 67]. Accordingly, increased 
production of malondialdehyde (MDA) was described as a consequence of GGT dependent lipid 
peroxidation of isolated LDL lipoproteins [68]. It is well established that LPO end-products (lipid 
peroxides, aldehydes, carbonyls) can damage DNA, either by reacting directly with bases, or by 
generating more reactive bifunctional intermediates forming exocyclic DNA adducts, DNA nicking 
and base substitutions [69]. 
Lipophilic antioxidants such as α-tocopherol or butylated hydroxytoluene were shown to exert strong 
protection against some types of such DNA damage [70]. Our results document a strong inhibition of 
GGT-dependent/iron-catalyzed DNA damage by α-tocopherol, butylated hydroxytoluene (a synthetic 
analogue of vitamin E) and Trolox C (a water-soluble vitamin E analogue). It is therefore conceivable 
that part of the observed GGT-dependent DNA damage may be mediated through the initiation of a 
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lipid peroxidation process, as previously observed in hepatoblastoma cells [71]; future studies will 
help elucidate this point. 
Thus, continuous direct production of DNA damage through a GGT-dependent promotion of iron-
dependent oxidative processes can represent a challenge to DNA-repair systems in GGT-expressing 
cancer cells, a condition likely leading to genomic instability and increased mutation risk. Modulating 
effects of pro-oxidants have also been reported with regards to DNA repair systems, such as, e.g. 8-
oxoguanine DNA glycosylase (OGG1). An oxidative-mediated downregulation of DNA repair would 
indirectly exacerbate genomic instability; further studies are however needed on these aspects [72].  
In conclusion, GGT-dependent DNA oxidative damage adds to previously described redox effects of 
this enzyme, such as direct oxidative damage to lipids and proteins, modulation of intracellular 
antioxidants, such as GSH [62] and catalase [27], and regulation of redox-sensitive molecular targets 
relevant to cell proliferation ability and cancer growth, like NF-kB and AP-1 [73, 61] and TNFR-1 
[74]. 
The kidney represents an organ where initiation/progression of neoplastic transformation mediated 
through GGT-dependent redox processes may represent an important mechanism. The kidney is in 
fact very rich in GGT activity, expressed in tubular epithelial cells and participating in resorption of 
GSH from preurine, and it was repeatedly shown that treatment of animals with chelated iron results 
in lipid peroxidation and induction of kidney carcinomas [64, 75]. Moreover, it is known that 
oxidative conditions occurring during inflammation can induce the expression of GGT [76], and it has 
been recently shown that the pro-inflammatory cytokine TNF-alpha – implicated at several levels in 
cancer progression – induces GGT expression via NF-kappaB-dependent pathways [77]. 
It can thus be envisaged that GGT-dependent genomic instability might contribute to the pathogenesis 
of inflammation-related neoplasia. 
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